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Diabetic Nephropathy (DN) is the leading cause of end stage renal disease and mortality in 
diabetic patients. Over the years, medicinal plants have been used to manage diabetes and its 
complications. Metformin, the synthetic analogue of galegine is used as first line therapy for 
Diabetes Mellitus (DM) but its use is contraindicated in patients with kidney dysfunction. The 
management of DN currently is limited to the use of anti-hypertensive agents; ACE inhibitors 
and angiotensin receptor blockers. Grapefruit juice (GFJ) has shown potential as an anti-
diabetogenic agent because of its ability to ameliorate hyperglycaemia and dyslipidemia but its 
effect on fluid and electrolyte disturbance is not known. This study was designed to investigate 
the effect of GFJ on renal dysfunction in streptozotocin (STZ) induced male wistar rats. 
Materials and Methods  
 
Male wistar rats weighing between 250-300g were divided into 7 groups (n=7) and kept in cages 
for the treatment period of 8 weeks. Laboratory conditions of 12 hour light/dark cycle, 
temperature 25±2
0
C and humidity 50-55 % were maintained throughout the study period. Non-
diabetic animals group 1 (Control) were treated orally with 1.0 ml /Kg BW of distilled water, 
while group 2 (ND-GFJ) were treated orally with 3.0 ml /kg BW of GFJ. The diabetic groups 3, 
4, 5, 6 and 7 were starved overnight in preparation for the STZ injection. Fasting blood glucose 
concentration was obtained via tail prick before 45 mg or 60 mg of STZ was administered via a 
single injection in the peritoneal cavity. STZ was prepared by dissolving it in 0.2 ml of 0.1 M 
Citrate buffer at pH 4.5. Groups 3, 4 and 7 received 60.0 mg/ Kg BW of STZ while group 5 and 
6 received 45 mg/kg  BW of STZ. Three days following STZ induction, the diabetic state was 
confirmed by measuring fasting blood glucose and animals with glucose concentration greater 
than 6 mmol/L were included in the study.  Group 4 (INS- D60) and group 5 (INS- D45) were 
additionally treated with 4.0 U/kg BW of insulin via subcutaneous injection (S.C) twice a day 
while Group 6 (GFJ-D45) and group 7 (GFJ-D60) were treated orally with 3.0ml/Kg BW of 
GFJ. Group 3 (D-60) were similarly treated with 1.0 ml /Kg BW of distilled water. Fasting blood 
glucose (FBG) and glucose tolerance tests (GTT) were done on days 1 and 58 respectively in all 
the treatment groups. Urine was collected for a period of 24 hours on day 59 and on the last day 
xv 
 
animals were sacrificed by halothane overdose. Blood samples were obtained via cardiac 
puncture; kidney tissues were removed and preserved in formalin while the liver was snap frozen 
with liquid nitrogen and stored in a freezer (-80
0




Reduced plasma insulin was accompanied by decrease in body weight and an increase in FBG 
accompanied by polyuria, polydipsia and glucose intolerance in the non-treated diabetic animals 
compared to the control. Fasting blood glucose was significantly (p<0.0001) increased in the 
diabetic groups and treatment with GFJ or insulin lowered FBG in groups (GFJ-D45, GFJ-D60 
& INS-D60) compared to the diabetic control (D60). GFJ significantly (p=0.0034) improved 
glucose intolerance in diabetic animals (GFJ-D60 & GFJ-D45) when compared to diabetic 
control groups D-60 & D-45 respectively. Hepatic glycogen content was reduced in diabetic 
animals (P=0.024) and treatment with GFJ significantly (P=0.00016) increased the glycogen 
concentration. In the non-diabetic group (GFJ-ND) treatment with GFJ significantly (P=0.0013) 
increased the glycogen concentration when compared to the control group. In the diabetic 
animals, decreased GFR was accompanied by Na
+












  in the diabetic group (GFJ-D60) but did not increase urinary Cl
-
 in non-diabetic group and  
consequently improved GFR in the diabetic group. Renal pathology showed structural changes in 
the glomerulus and treatment with GFJ had some reno-protective effect. 
 Conclusion  
 
GFJ lowered the fasting blood glucose and improved glucose tolerance in the STZ-induced 
diabetic rats in a comparable manner to insulin treated diabetic rats. GFJ decreased Na
+
 retention 
and increased GFR in the diabetic animals. This study suggests that GFJ could ameliorate 
nephropathy associated with diabetes mellitus. These results are the first to show that GFJ has 
renoprotective effects in STZ-Induced diabetic rats. 
 





1.1 Introduction  
 
The global flora consists of millions of different plant species that have served man well 
throughout history with over 20,000 species that are of huge importance because of their 
medicinal value
 (1)
. Plants contain a number of bioactive compounds (phytochemicals) which 
have been exploited by man due to their desirable physiological and biochemical effects. In 
general, phytochemicals are not essential for sustaining life but they contribute significantly to 
optimal health 
(2)
. The use of plants for medicinal purposes dates to antiquity, the first records 
were found in Egypt around 1550 BC and Babylon circa around 1770 BC in the code of 
hammurabi
 (3) (4) (5)
. Ethno-botanical reports from around the world show that there are at least 
800 plant species that may possess anti-diabetic properties 
(6) (7) (8) (9) (10) (11)
. Galega officinalis is 
an example of a plant that was used in the medieval times to manage diabetes mellitus. Around 
the 1960s the bioactive compound galegine or isoamylene guanidine was extracted from the 
plant to produce phenformin and buformin but they were removed from the market in the 1970s 
because of their life threatening side effects
 (12)
. Galegine was then modified to produce a 
synthetic analogue known as metformin, which has a lower incidence of lactic acidosis in 
comparison to its predecessors. 
 
High costs associated with pharmacological agents used to manage diabetes and their associated 
side effects have seen people going back to the ways of their forefathers in the use of medicinal 
plants to manage common ailments. The safety and efficacy of these plants have not been 
established and this has lead researchers to look into ethno-medicinal claims and folkloric use of 
medicinal plants to ascertain their safety, efficacy
 
and viability for the development into novel 
therapeutic. The use of complementary and alternative medicine has increased over the years 
because they are perceived to be safer, cheaper, and harmonious with the environment
 (13)
. The 
search for novel anti-diabetics that would alter disease progression and or complications, be cost 
effective and have fewer side effects has captured the interests of researchers. 
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1.2 Background  
 
Grapefruit is a classic example of a citrus fruit that is widely cultivated across the globe and its 
geographical distribution is in tropical and sub-tropical regions. This fruit is eaten as a whole or 
processed into thirst quenching juice that has gained global popularity because of its taste, 
nutritive value and potential health benefits associated with its consumption 
(13) (14)
. Grapefruit‘s 
global production has increased steadily with approximately 6.23 million tonnes produced in 
2010
 (15)
. It flourishes in tropical to subtropical regions in South Africa, United States 
(16) (17)
, 
Israel, Argentina, Cuba, and Mexico 
(13)
. In South Africa, the geographical locations that favour 
citrus fruit production are: Eastern Cape, Kwazulu-Natal, Northern Cape, Mpumalanga and 
Limpopo with the latter 2 being the highest grapefruit producing areas
 (17)
 (Figure1). The 
percentage usage of the land allocated for grapefruit production in the 2 provinces is 37 % and 
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Figure 1: Citrus (Grapefruit) Growing Areas in South Africa
 [16]
 















Table 1: Percentage land usage for Grapefruit Production in South Africa 
[16]
 
1.3.0. Grapefruit  
 
1.3.1. History of Grapefruit 
 
The history of grapefruit dates back to the 16
th
 century during the time of Christopher Columbus 
when he first brought the citrus biotypes to the Caribbean
 (18)
. Literature in botanical journals 
shows that the grapefruit‘s origin is in the tropical and sub-tropical regions in the West Indies. 
This citrus fruit was first mentioned, described and recorded by Patrick Browne in the in 17
th
 
century as the ―forbidden fruit‖ or ―smaller shaddock‖ 
 (15)
 and was introduced to Florida in the 
1820s
 (19)
. In 1830, James Macfayden a botanist, named a fruit from the botanical family rutaceae 




Commercial production of grapefruit began in the late 1880 in the United States
 (22) 
and then it 
spread to other countries. According to chemotaxonomic evidence based on molecular biology 
and tests such as Random Amplified Polymorphic DNA (RAPD) and sequence characterized 
amplified region (SCAR)
 (23)
 shows that grapefruit has a total of 72 genetic markers
 (23)
 . Out of 
the 72 genetic markers found in grapefruit, forty-five of the markers can be traced back to the 




This offered proof that the apomictical fruit 
originated from two different citrus fruits from the rutaceae family. Natural hybridization 
between the pummelo/ shaddock (Citrus grandis) which was the maternal progenitor and the 
sweet orange (Citrus sinensis) which was the pollen parent resulted in the grapefruit (GF)
 (20) (25) 
(26) (27) (28)
. 
Province Area (HA) Grapefruit Percentage 
Limpopo 18,146 37% 
Mpumalanga 12,050 30% 
Kwazulu-Natal 3,824 20% 
Eastern Cape 12,162 2% 
Northern Cape 871 1% 
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1.3.2. Grapefruit Morphology  
 
The grapefruit tree is an evergreen tree that grows to a height of about 4.5 – 6.0 meters and its 
leaves are light green in colour when young and they become darker as they mature. The leaves 
on the grapefruit tree are characterised as simple and can be as long as 3-5 inches with large 
winged petioles and shiny with a broad base and a narrow apex. It is a flowering plant that 
produces white flowers and the fruits produced are large with thick rinds (hesperidium) that grow 
in clusters like gigantic grapes so it received the name grapefruit ( Figure 2) 
 (29) (30)
. The fruits 
are pale yellow when ripe because of the breakdown of chlorophyll into xanthophyll and 
carotene which are yellow and orange respectively 
(30) 
with β-citraurin being the major 




































1.3.3. Varieties of Grapefruit 
 
All grapefruit cultivars are from the same ancestral tree and this has been confirmed by inter-
simple sequence repeat (ISSR) markers 
(33)
. Originally, the first grapefruit pulp was white but 
with the dawn of the 20
th
 Century, citriculturists propagated different strains that varied from 
pink to slightly reddish in colour (Figure 4) 
(19)
. The development of new grapefruit varieties was 
done through selected somatic mutations in the bud and or branches. The pink fleshed cultivars, 
arose from bud mutation
 (22)
 and mutation in the periclinal chimera branches of mash and waters 
gave rise to the Thompson cultivar (Figure 4)
 (34)
. Varieties of grapefruit  are as a result of 
artificial mutation by selection of desirable traits i.e. increasing redness, reduction in the number 




These mutations showed an increase in certain pigments like 
lycopene and carotene in the endocarp, rind and or pulp
 (34)
. In South Africa, the cultivars 
commonly grown are star ruby and mash. Other varieties available in the global market can be 
categorised into two major groups according to the pulp colour and their seed content (Table 2).  
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1.3.4. Medicinal Properties 
 
The consumption of fruits and vegetables  have  gained importance due to their acclaimed effects 
that could help reduce the progression of certain diseases and or conditions that affect the 
endocrine system like diabetes and its related complications
 (35) (36)
. Over the years grapefruit has 
received a lot of attention globally because of its acclaimed medicinal properties. GF has  been 
used in the management of insomnia, anxiety, dysuria, cancer, anorexia, rheumatism and 
cardiovascular disorders
 (19)
. Scientific research conducted on the whole fruit and its juice has 
suggested that this fruit could be having a plethora of beneficial medicinal effects which have 
justified and re-enforced its ethno-medicinal uses. Experimental evidence has shown that 

















, cardio-protective protective effects 
(42) (43)




A study done by Fujioka et al.
 (44)
 showed that grapefruit could be beneficial to obese patients 
because it helps improve insulin resistance in patients with metabolic syndrome as compared to 
placebo 
(44)
. Grapefruit juice (GFJ) has a high nutritive value, it provides 69% of the 
recommended daily allowance for vitamin C 
(19)
, which is a potent antioxidant, it is rich in folic 
acid, pectin, carotenoids and potassium 
(36) (45) 
. In Vitro studies have shown that the bioactive 
compounds in GFJ could elicit their pharmacological properties through the regulation of certain 
enzyme systems like the kinases
 (46) (47)
, phospholipases, ATpase, lipooxygenase and 








Research conducted on grapefruit has led to the characterization and isolation of the different 
bioactive compounds found in the whole grapefruit (pulp, peel and juice). There are four 
different flavonoids found in the grapefruit namely flavonones, flavones, flavonols and 
anthocynanins 
(25)
. Flavonoids are secondary plant metabolites which are diphenylpropane 
derivatives that are responsible for the taste, colour and a wide range of biochemical and 
pharmacological effects associated with grapefruit consumption 
(25) (35) (47) (49)
. There are more 
than 5000 flavonoid compounds that can be categorized into 10 - 13 chemical groups
 (50) (51)
 with 
approximately 500 occurring in their aglycone form and the rest as O- or C-glycosides 
(52)
. The 
basic flavonoid structure is a benzo-γ-pyrone (Figure 5) and addition of different functional 
groups like the hydroxyl, methoxyl, and o-glycoside to the basic structure 
(42) (51) 
leads to the 
formation of the different subclasses. Flavones, flavonols and flavonones are classified according 












                        




Flavonoids are natural antioxidants and they have proven to be an efficient defence system in 
fighting against  formation of free radicals
 (53) (54) 
such as hydroxyl (HO
-









) and singlet oxygen 
(52) (53) (55) (56)
. Reactive 
oxygen species (ROS) have been associated with destruction of cell membranes, proteins, β-cells 
and deoxyribonucleic acid (DNA) 
(53)
. The human body has enzymatic and non-enzymatic 
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defence systems that help prevent the damage of cells and tissues (Table 3) but their depletion or 
reduced production has been associated with degenerative conditions
 (53)
. Flavonoids can prevent 
oxidative damage by chelating with transitional metals or by inhibiting the enzymes that are 
required for the initiation reactions
 (57)
 such as xanthine oxidase and protein kinase C (PKC) 
(53)
. 
In addition, they can increase the body‘s intracellular glutathione, which is part of the 








Enzymatic Defence System 
 
Non-Enzymatic Defence System 
 
 Catalase metabolises hydrogen 
peroxide H2O2, 
 Superoxide dismutase enzyme 
metabolises Superoxide  anion (O2
-
) 
and lipid peroxidise inhibiting 
hydroxide formation 
 
 Iron binding proteins transferin and 
ferritin ( Iron is a Pro-oxidant metallic 
ion) 
 Dihydrolipoic acid 
 Reduced CoQ10 
 





The flavonoids naringin and hesperidin are the most abundant bioactive compounds found in 
grapefruit (Table 4) 
(36) (58)
. Naringin, hesperidin and limonin are responsible for the fruits bitter 
taste and the furocoumarins cause alteration of drug pharmacokinetics
 (25) (31) (48)
. The quantity of 
phytochemicals found in grapefruit varies according to geographical location which determines 
the environmental conditions; the time of harvest determines the maturity and development, the 
variety, season and the methods used to process and treat the fruit after harvesting
 (34) (46) (48) (59) 
(60)
. The highest concentration of flavonoids and furocoumarins are found during the early stages 
of development and this decreases with maturity of the fruit 
(36)
. Amongst the different grapefruit 
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cultivars star ruby has the highest concentration of naringin, narirutin and neohesperidin (Table 
4). The flavonoids in citrus fruits exist as flavones and flavanone glycosides
 (61)
 which are known 





, cyclic GMP phosphodiesterase, cyclic AMP 
phosphodiesterase, angiotensin converting enzyme and thyroid peroxidase
 (52) (53)
 by as yet 
unknown mechanism. Naringin and hesperidin are glycosides that are hydrolyzed at the intestinal 
brush border to their various aglycones naringenin, hesperetin and a sugar 
(52)
 by the intestinal 
enzymes naringinase and α-L-rhamnosidase respectively 
 (58) (63) (64)
(Figure 6 and 7). Glycosides 
differ from the aglycones in that they lack a sugar moiety attached to the hydroxyl group at C-3 
or C-7 
(65)
. The common sugar moieties on the glycosides are D-glucose and L-rhamnose 
(65)
 and 
they make the aglycones more soluble 
(50)
. Naringenin and hesperetin appear to be the 
pharmacologically active forms but their actions differ significantly in terms of their 





Table 4: Potential Bioactive compounds found in Grapefruit Juice 
(35) (46) (66) (67) 
 
In addition to flavonoids grapefruit juice also possesses inorganic elements that play an essential 












































































15.84±0.22 13.70±0.04 13.90±0.012 16.30±0.14 
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metalloproteinases and some can preclude development of certain complications associated with 
diabetes 
(68)
. Several studies have highlighted the importance of zinc and selenium in 













































Figure 6: Enzymatic hydrolysis of naringin to its active aglycones, naringenin 






















Figure 7: Enzymatic hydrolysis of hesperidin to its active aglycones, hesperetin 
(73) (58) (63) (74)
. 
1.4.1 Flavonoid Glycosides Metabolism  
 
 Flavonoids are metabolised in the liver, intestinal wall and lumen before their metabolites are 
absorbed into the systemic circulation
 (65)
. Gastrointestinal bacteria like Bacteroides JY-6 
(75)
, 
Streptococcus faecium VHG-1, Streptococcus sp. FRP-17, Escherichi coli HGH21 and HGH6 
are known to produce enzymes that hydrolyse glycosides to their various aglycones (Figure 6 
and 7). The enzymes lactase phlorizinhydrolase
 (75)
 and α-rhamnosidase 
(65)
 are associated with 
glycoside deglycosylation. Some of the absorbed flavonoids undergo conjugation reactions by 
hepatic enzymes but a majority of the flavonoids are broken down by the intestinal micro flora 
(53)
. The aglycones are degraded further through c ring fission
 (52) (76)
 and the products are 
absorbed into the blood stream and they undergo methylation, glucuronidation, sulfation 
(75) 
and 









Table 6:  Flavonoids Found In Grapefruit with potential anti-diabetic properties 
(50) (61)
 



















 Hesperidin causes Upregulation of 



















 ↓ Blood glucose and stimulates 
glucose uptake by altering intrinsic 





1.5.0. Grapefruit Drug Interactions 
 
The drug interactions associated with GFJ consumption were first discovered 
accidentally in 1989 during a study that was examining the interaction of ethanol and 
felodipine when grapefruit was used to mask the taste of ethanol 
(21)
. It was observed 
that GFJ altered the pharmacokinetics of felodipine and subsequent studies have 
confirmed that this effect is indeed a cause of concern because many patients take 
their medication with GFJ and this can lead to life threatening toxicity due to 
increased drug bioavailability 
(25) (36) (48)
. The interactions between GFJ and 
prescription drug is limited only to oral dosages and no interactions have been noted 
when the drugs are administered intravenously 
(21)
. GFJ has been known to interact 
with up to 50% of prescription drugs such as; calcium channel blockers, cholesterol 
lowering drugs ; statins, protease inhibitors, benzodiazepines and phosphodiesterase 
inhibitors 
(21) (36) (81) (82) (83) 
(Table 7).  
 
1.5.1. Mechanism of Grapefruit Juice Interactions 
 
The major drug metabolising enzyme systems in the body are the Cytochrome P450 
(CYP450) predominantly found in the liver and small intestines with drug specific 
isoforms 
(48)
. The CYP450 enzyme systems are responsible for the biotransformation 
of a number of drugs before they reach the systemic circulation by first pass hepatic 
metabolism. GFJ has shown significant activity in altering the functioning of 
xenobiotic metabolizing enzymes (CYP450) and or transporter proteins in the 
intestines 
(84) (85)
. Bioactive compounds found in GFJ such as furanocoumarins are 
potent inhibitors of CYP450 system 
(86)
 especially the CYP3A4 isoform which is 





GFJ inhibits the cytochrome CYP3A4 and alters the functioning of 
drug transporter proteins namely P-glycopoteins (P-gp), human organic cation 
transporter protein (OCT) and human organic anion transporting polypeptides 
(OATP) 
(48) (83) (84)
. Bergamottin and 6'7'-dihydroxybergamottin are example of 
furanocoumarins (Figure 8) that have been identified and isolated from GFJ and have 
been found to irreversibly inhibit CYP3A4 enzyme by mechanism based inactivation 
(88) 
causing an increase in the plasma concentration of CYP3A4 substrate drugs (Table 
7)
 (21) (31) (89) (83) (88) (89)
. P-glycoprotein is an efflux pump located on the apical brush 
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border of enterocytes that transports drug substrates from the enterocyte into the gut 
lumen thus decreasing oral bioavailability 
(90)
. The effect of grapefruit juice on the 
efflux pump is very controversial with reports ranging from inhibition to its activation 
(91)
. The study done by Wang et al.
 (85) 
showed that bergamottin inhibited the P-gp 
efflux pump in a concentration dependent manner resulting in increased oral 
bioavailability of digoxin.  
 
OATP is a drug uptake transporter that is from the solute carrier super family (SLC). 
Its expression is similar to that of P-gp and it plays a major role in the transportation 
of drug substrates into the cell. A study done by Dresser et al. 
(91) 
showed that the 
furanocoumarin (6‘7‘-dihydroxybergamottin) inhibited the activity of rat organic 
anionic transporting polypeptide 3 and 1(oatp3 and oatp1) and human OATP activity 
resulting in increased plasma concentration. In addition GFJ flavonoids naringin and 
hesperidin have also been implicated in the inhibition of OATP1A2 in vitro 
(92)
. GFJ 
furanocoumarins monomers, dimer 
(93)
 and naringenin can therefore alter the activities 
of p-glycoprotein / Multidrug resistant protein 1(MDR1) and the OATP which play a 













                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Table 7: List of drugs that grapefruit increases their serum concentration. 
 
Class of Drug 
 
Example of Drug References 
Antiarrhythmics 
 






Midazolam, Triazolam, Buspirone 
 


























Felodipine ,Verapamil, Amlodipine, 
Nicardipine, Nimodipine, Nifedipine 
 
 
(21) (25) (31) (81) 
(88) (93) 




Artovastatin, Simvastatin, Lorvastatin 
 








Ciclosporin, Tacrolimus, Sirolimus 
 

























1.5.2. Flavonoids with Potential anti-diabetic Activity. 
 
Flavonoids like naringinin and hesperitin found in GFJ have shown to have an array 
of pharmacological activities that would be beneficial to a diabetic patient. Naringin 
has been shown to reduce the activities of phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6- phosphatase
 
key enzymes in the gluconeogenesis process in 
the liver 
(79)
 and it has the potential to ameliorate diabetic artherogenic dyslipidemia 
(39)
. The ability of hesperitin and naringenin in inhibiting key enzymes involved in the 
synthesis of cholesterol such as 3-hydroxy-3-methyl-glutaryl- Coenzyme A reductase 
(HMG-CoA reductase) and acyl-CoA: cholesterol acyltransferase (ACAT)
 (95) (96)
 
suggests that they could be potent hypocholesterolemic agents. Chanet et al 
 (97) 
 
showed that consumption of naringin significantly reduces diet-induced 
atherosclerosis in mice 
(88)
. This is because naringenin increases the expression of low 
density lipoprotein receptors (LDLR) in HepG2 cells by activation of mitogen–
activated protein kinase (MAPK) and phosphoinositide-3-kinase (PI3-K)
 
mediated 
uptake of serol regulatory element binding protein (SREBP) 
 





Experimental evidence suggests that naringenin can also inhibit the microsomal 
triglyceride transfer protein activity causing a decrease in blood lipids and fatty liver 
(95) (97)
. In addition to that, the aglycone hesperitin improved the atherogenic index in 
experimental rats 
(99)
. The hypoglycaemic effects of GFJ bioactive constituents have 
been reported, suggesting that naringenin can decrease glucose uptake in the renal and 
intestinal tissues because it inhibits the sodium – glucose co-transporter 2 (SGLT 2) 
(80)
. In the skeletal muscle, naringenin increases glucose uptake via activation of 
AMP-activated protein kinase (AMPK) 
(100)
 significantly reducing the plasma glucose 
concentration. Other mechanisms by which GFJ lowers blood glucose concentration 









The public health sector in both the developed and developing countries alike are 
plagued with the burden of non-communicable diseases like diabetes. Studies show 
that diabetes will affect many people in developing countries because of lack of 
effective and affordable treatment
 (101)
. Global data shows that approximately 130 
million
 (102)
 people are suffering from diabetes mellitus and by the year 2030 the 
number of people suffering from diabetes will be in the region of 366 million
 (103) 
and 
this could rise to 522 million as stated during the world diabetes day in Brussels on 
the 14
th
 of November 2011 
(104)
. Epidemiological data shows that diabetes and its 
related complications will have negative impact on the general population due to the 
unprecedented increase in healthcare costs associated with their management which 
can significantly cripple the struggling economies and if not managed properly 
leading to increased mortality rates in affected populations.  
 
In South Africa, it is estimated that 11.5 million people suffer from diabetes mellitus 
(103) (105) 
and this figure is expected to rise due to prevalence of obesity, sedentary 
lifestyles, urbanization 
(106) (107) 
and physical inactivity 
(103) 
. The population groups in 
South Africa mostly affected are the black, coloured and Indian communities. Shaw et 
al
 (107)
 predicts that South Africa‘s national prevalence by the year 2030 will be at 
4.9% with a mean yearly increment of 18,000 people affected with diabetes 
(107)
.  
1.6.2. Definition and Classification 
 
According to the 1999 World Health organisation (WHO) consultation report, 
diabetes mellitus was defined as ―a metabolic disorder of multiple etiology 
characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and 
protein metabolism resulting from defects in insulin secretion, insulin action, or both‖
 
(108)
 . Diabetes mellitus can be categorised into two major groups depending on the 
exogenous insulin requirements. The two major groups are type 1 which is also 
known as insulin dependent diabetes mellitus (IDDM) and type 2 which is the non-
insulin dependent diabetes mellitus (NIDDM) 
(102) (109)
. Type 2 diabetes is the most 
common form and it accounts for 90-95% of all diabetic cases affecting the general 
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population while Type 1 accounts for 5-10% and generally affects children 
(101) (102) 
(110) (111) 
. Other forms of diabetesidentified are gestational diabetes (GD) and Maturity 
onset diabetes of the young (MODY). GD develops during pregnancy causing 
dysfunctions in the carbohydrate metabolism due to acquired insulin resistance 
resulting in chronic hyperglycaemia in the mother 
(112)
. It is characterised by glucose 





Maturity onset diabetes of the young (MODY) on the other hand occurs in non-obese 
adolescents. MODY also referred to as monogenic diabetes and can be classified 
according to where the single point mutation occurred, i.e. if it occurred on the 
metabolic enzyme or the transcription factors. Mutation of the glucokinase enzyme 
leads to MODY subtype 2 (MODY 2). The other subtypes of MODY occur due to 
mutation of different transcription factors namely; hepatocyte nuclear factor (HNF) - 
4alpha, HNF-1alpha, HNF-1 beta, insulin promoter factor (IPF-1), neurogenic 
differentiation factor 1(NeuroD1) accounting for the other 5 subtypes 
(113) (114) (115)
. 
MODY2 is associated with reduced glucose induced insulin secretion that is 





1.7.0 Aetiology and Pathophysiology of Diabetes Mellitus 
 
Diabetes affects the endocrine tissues of the pancreas leading to a disruption in the 
negative feedback mechanism of the body that is involved in blood glucose 
regulation. Destruction of the pancreatic β-cells can lead to an absolute or relative 
insulin deficiency as seen in diabetic patients. A number of factors have been known 
to cause the destruction and or dysfunction of pancreatic β-cells located in the islets of 
langerhans. The identified factors include; autoimmune diseases, genetic defects of 
the pancreatic β-cells, defects in insulin action, environmental toxins, viruses and 
drugs or chemical agents like streptozotocin and alloxan 
(109)
. Streptozotocin (STZ) is 
a nitrosourea analogue that has high specificity for the pancreatic β-cells. It was first 
isolated from Streptomyces achromogenes a soil microbe and used for the treatment 
of pancreatic β-cell carcinoma 
(117) 
. It works by destroying the β-cells through the 
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generation of super oxide anions that act on the mitochondria causing an increase in 
the activity of the enzyme xanthine oxidase 
(118) 
causing total or partial destruction of 
the pancreatic β-cells. The administration of streptozotocin 60mg/BW and 45mg/BW 
has been shown to create type 1 and type 2 diabetic models respectively. The 
difference in the dosage causes i.e 60mg/BW causes complete destruction while 
45mg/Kg causes partial destruction of the pancreatic β-cells. The destruction leads to 
a significant drop in insulin levels and ultimately no insulin production and this 





The clinical symptoms associated with diabetes are because of chronic 
hyperglycaemia and the response of the body in trying to correct the imbalance. The 
normal range for blood glucose concentration is around 3.3 mmol/L - 8.3 mmol/L 
depending on the fed or fasted state of the person
 (119)
. Diabetic patients experience 
impaired Fasting Blood Glucose (FBG) and glucose intolerance with FBG greater 
than 6.7 mmol/L
 (120)
. The glomerulus filters a large volume of glucose from the blood 
stream and it is usually reabsorbed in a multiple step process via sodium glucose co-
transporter 2 (SGLT2) in the proximal convoluted tubule and GLUT-2 transporters at 
the basolateral membrane and back into the blood stream 
(121)
. Glomerular filtration of 
glucose and subsequent reabsorption increases in a linear manner with an increase in 




The renal tissues of diabetic patients cannot maintain the FBG at approximately 5.6 
mmol/L due to increased glucose reabsorption 
(122)
. When glucose concentration is 
above the theoretical threshold of 11 mmol/L, saturation of the glucose reabsorption 
transport system occurs causing excess glucose to be excreted in the urine 
(glycosuria) Figure 9 
(122) (123) 
.Glucose excretion in the urine is accompanied by 
increased loss of water and electrolytes (polyuria) as observed in patients suffering 
from diabetes. This process causes dehydration and the body attempts to correct the 




















Figure 9: Renal glucose handling adapted with permission from Defronzo et al 2012 
(122)
. 
1.7.2. Type 1 Diabetes  
 
In type 1 diabetes, multiple factors can cause destruction of the β-cell as previously 
discussed but autoimmune response in genetically predisposed children is the most 
common form that affects type 1 diabetic patients resulting in an absolute deficiency 
of insulin production
 (111) (125) (126) (127)
. Genetically predisposed individuals possess the 
human leukocyte antigen genotypes (HLA) on the DR and DQ especially on HLA 
DR3 and HLA DR4
 (111) (124) (128)
 making them more susceptible to the development of 
type 1 diabetes after an environmental trigger. HLA-chromosome 6 is the genetic 
portion that is linked with inheritance from parent to the child 
(111) (125)
. Genetic 
susceptibility involves HLA and other genetic factors like the insulin gene on 
chromosome 11 and cytotoxic-T-lymphocyte antigen (CTLA-4) on chromosome 2 
(125)
. Some of the environmental triggers identified are enteroviruses, cox sackie, 
congenital rubella, toxins from foods and or chemical agents. They can trigger an 
autoimmune response in a genetically susceptible individual who has one or more 







Insulin, glutamic acid decarboxylase (GADA) and protein tyrosine phosphatise (IA2) 





Studies have shown that T-cells, macrophages / dendritic cells, β-cell 
autoantigens and cytokines are implicated in the pathological development of type 1 
diabetes 
(129) (130)
. The failure of the immunoregulatory system causes auto-reactive T-
cells to activate Th1 that promotes inflammatory immune responses and suppresses 
Th2, which is a subset of the CD4
+ 
T–cells responsible for humoral immunity 
(131)
. 
The T- cell lymphocyte Th1 causes the secretion of inflammatory mediators namely; 
interleukin 2 (IL-2), interferon gamma (IFN-γ), tumor necrosis factor beta (TNF-β), 
tumor necrosis factor alpha (TNF-α) 
(132) (131)
. These cytokines cause the recruitment 
of circulating leukocytes into the islet cells and this leads to the activation of 
macrophage elimination of antigen bearing cells. This is because the autoantibodies 
attack the β- cell specific autoantigens on the cell surface leading to the activation of 
cytotoxic T cells by IFN-γ and IL-2 resulting in an inflammatory response that causes 




1.7.3. Type 2 Diabetes  
 
In type 2 diabetes, genetic predisposition and a combination of environmental factors 
intertwined together lead to the dysfunction and eventual destruction of the pancreatic 
β-cells
 (133)
. Some of the genetic variants that are associated with type 2 diabetes are 




the Japanese population, 
KNCNQ1 gene that encodes for pore forming subunit in voltage gated K
+
 channels in 
East Asians and Europeans
 (134) 
. These genetic variations in addition to environmental 
factors like diet, obesity and sedentary lifestyle increase the risk for development of 
type 2 diabetes. Type 2 diabetes is characterised by hyperglycaemia, declining beta 
cell function 
(135)
, impaired glucose tolerance, insulin insufficiency 
(136) 
and reduced 
insulin mediated glucose uptake and utilization (insulin resistance)
 (102)
. Insulin 
resistance (IR) is a major problem because of the fatal clinical consequences 
associated with its development. Resistance to the action of insulin in the hepatic 
tissues causes increased glucose and VLDL production, in the adipose tissues, 
increased release of free fatty acids (FFAs) and in the skeletal muscle reduced glucose 
utilization 
(119)
. A number of abnormalities on the insulin receptors found in different 
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tissues, increased FFAs accumulation, obesity, diseases like Cushing‘s syndrome, 
acromegaly, glucogonoma and or genetic defects can cause insulin resistance. In 
diabetic patients , IR  can develop due to accumulation of intracellular fatty acid 
metabolites that prevent the activation of phosphoinositide -3- kinase (PI3-kinase) 




This can cause severe problems that could lead to the development of 
hyperglycaemia induced tissue damage, dyslipidemia, CVD, hypertension, metabolic 
syndrome and or progression of β-cell dysfunction.  
1.7.3.1. Pancreatic Beta (β) Cell Dysfunction 
 
The pancreas is an organ with exocrine and endocrine tissues that plays a major role 
in the production of hormones that are responsible for blood glucose regulation
 (139)
. 
This organ consists of two major segments namely the acini and islets of Langerhans. 
The islets of Langerhans comprise of four distinct cells namely the alpha, beta, delta 
and F-cell. The β-cells form bulk of the cells followed by the alpha and delta cells 
respectively
 (140)
. The islets of Langerhans‘ major role is the production of insulin, 
glucagon and somastatin released from the beta, alpha and delta cells respectively.  
The β-cell is susceptible to destruction by chemical agents, hyperglycaemia and 




In type 2 diabetes, pancreatic β-cell toxicity results from chronic hyperglycaemia and 
increased intra–islet lipid accumulation 
(135)
. The generation of reactive oxygen 
species (ROS) due to glucose toxicity, a dysfunctional mitochondrial system and 
formation of advanced glycation end products (AGE) causes increased oxidative 
stress that lead to the progression of β-cell dysfunction 
(141)
. This is because the 
pancreas lacks a natural defence system against oxidative stress due to lack of the 
glutathione peroxidase-1 (GPx-1) gene 
(141) (142) (143)
. The loss of β-cell mass leads to 
insufficient insulin production and this causes decreased glucose transport in fat and, 






1.7.4. Glucose Homeostasis  
1.7.4.1. Insulin  
 
Insulin is an anabolic, pleiotropic hormone that works by controlling the expression of 
different genes encoding for metabolic enzymes required for glycolysis and inhibition 
of glycogenolysis, and the gluconeogenic processes 
(119) (138)
. A rise in blood glucose 
concentration above 8.3 mmol/L and an increase in amino acid levels after a meal 
stimulate the release of insulin from the pancreatic beta cells through an intricate 
process
 (145)
. This multiple step process is triggered by movement of glucose via 
facilitative diffusion aided by GLUT-2 transporter proteins located on the surface 
membrane of the pancreatic β-cells 
(138)
. Once in the cell, glucose is phosphorylated to 
glucose -6- phosphate catalysed by the glucokinase enzyme but this process is 
blocked in people with genetic mutation of the glucokinase gene and this results in 
reduced glucose stimulated insulin secretion
 (146) 
.The metabolism of glucose 
(glycolysis) causes the generation of ATP and a rise in the ATP/ADP ratio causing the 
inhibition of the ATP sensitive K
+
 channel. Intracellular build-up of K
+
 causes 





The influx of calcium into the cells causes insulin containing granules to fuse with the 





Hormones released after a meal cause the second phase of insulin release. These 
hormones are glucagon like peptide -1 (GLP-1) and vasoactive intestinal peptide 
(VIP)
 (148)
. The activation of phospholipases and protein kinase C by acetylcholine 
causes the stimulation of adenylyl cyclase activity that leads to the activation of 
protein kinase A which potentiates insulin secretion 
(149)
. This process of insulin 





Figure 10: Mechanism of insulin secretion in the pancreatic β-cells modified and 
adapted  from Rolland et al 2001
 (150)
  
1.7.4.2. Anabolic Effects of Insulin 
 
Insulin actions are initiated by its binding to the insulin receptors that are located on 
the plasma membrane in the liver, skeletal muscle and adipose tissues. The insulin 
receptors belong to a family of receptor tyrosine kinases that include insulin like 
growth factor and insulin- receptor- related - receptor 
(138)
. The insulin receptor is a 
heterotetrameric glycoprotein consisting of two α and β subunits
 (151)
. The binding of 
insulin on the α-subunit leads to auto phosphorylation of the tyrosine residue on the β 
subunits activating the intracellular signalling pathways responsible for insulin 
metabolic and mitogenic actions via activation of PI3-Kinase pathways 
(138) (145) (151) 
(152)
. PI3-Kinase catalyses the phosphorylation of phosphoinositides to 
phosphatidylinositol-3-phosphates resulting in the AKt / PKB activation and 
consequent gene expression and transcription of glucokinase, pyruvate kinase , fatty 
acid synthase and acetyl CoA carboxylase and the inhibition of transcription encoding 

















Figure 11: Signal transduction of insulin action adapted with permission from Satiel 
and Khan
 (138) 
a) Liver  
 
Insulin works directly via inactivation of glycogen phosphorylase (GP) which is the 
rate-limiting enzyme in glycogenolysis 
(153)
. This action inhibits the breakdown of 
glycogen to glucose-6-phosphate in the liver resulting in decreased glucose output 
(153)
. Phosphoenolpyruvate carboxylase (PEPCK) is an enzyme that catalyses the 
gluconeogenesis process from different substrates like alanine, pyruvate, amino acids, 
lactate and glycerol in the liver (Figure 12) 
[156]
. The down-regulation of genes 
encoding for PEPCK by insulin leads to reduced expressions of genes encoding for 
key glycolytic enzymes fructose-1-biophosphate and glucose - 6 - phosphatase in the 
liver ultimately reducing glucose output into the systemic circulation
 (138) (154)
 (Figure 
12) . In the Kerbs cycle, insulin stimulates the conversion of pyruvate to acetyl 








b) Skeletal Muscles  and Adipose Tissues  
 
Glucose transporters (GLUTs) are specialized hexose carrier proteins that are 
responsible for the movement of glucose in the different tissues
 (155) (156)
. The family 
of GLUT‘s has 13 known members divided into 3 classes. Class 1 consists of GLUT 
1- 4; class 2 GLUT 5,7, 9 and 11 class 3 GLUT  6,8 ,10 and 12 
(155)
. The transport 
process is an ATP-independent facilitative diffusion down a concentration gradient 
(155) (157) (158)
. Insulin promotes the transport and utilization of glucose in the adipose 
and skeletal muscle tissues by inducing the translocation of GLUT- 4 from the 
intracellular site to the plasma membrane via the PI(3)k pathway resulting in protein 
kinase B activation and subsequent decrease in circulating glucose 
(119)
. GLUT-4 is 
predominantly expressed in the adipocyte and muscle tissues
 (156) 
while GLUT 2 is 
expressed in the liver, pancreatic β-cells liver and kidney. In the adipocyte tissues, 
insulin causes the stimulation of lipid synthetic enzymes such as fatty acid synthase 
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(FAS), Acetyl CoA carboxylase (ACC) and pyruvate dehydriogenase and the 








Glucokinase (GK) is a glycolytic enzyme found in the parenchyma cells of the liver 
and pancreatic beta cells
 (159)
. Hexokinase I, II and III are isoforms of glucokinase and 
they differ in their affinity for glucose. The isoforms have a low affinity for glucose 
and physiological concentration of glucose 6-phosphate cannot inhibit their actions
 
(160)
. The difference between the hexokinase isoforms and glucokinase can be seen in 
their pharmacokinetics. When one looks at the glucose saturation curves produced by 





Variations of glucokinase activity in the hepatic and pancreatic tissues complement 
each other in maintaining homeostasis 
(162)
. In the liver it is involved in the catalytic 
process that promotes the phosphorylation of D-glucose to glucose -6- phosphate for 
utilization in the glycolytic process and other metabolic pathways and it  also acts as a 
glucose sensor in the pancreas 
(159) (163) (161) 
. The regulation of GK gene expression is 
tissue specific (hepatic or pancreatic) indicative of two specific promoters on the same 
gene
 (164)
. Liver GK is regulated by glucokinase regulatory protein (GKRP) which 
disrupts its catalytic actions 
(160)





This is because the mRNA of the liver and pancreatic glucokinase 
differs in the 5‘ portion of the coding accounting for the different regulators
 (163). 
GK 
governs the energy potential of the cell through oxidation and ATP generation 





 Glucokinase   




2. Glycogen Synthase  
 
Glycogen synthase (GS) is an enzyme located in the liver and muscle tissues and 
plays a pivotal role in glycogen synthesis. GS catalyses the addition of UDP- glucose 
to a non-reducing end of a glycogen chain through α-1, 4-glycosidic bonds 
(166) (167) 
(168)
. GS only catalyses the bonding of UDP-glucose to an already existing glycogen 
chain with 4 sub units while de-novo glycogen synthesis is catalysed by glycogenin 
which is a glycosyltransferase. Autoglycosylation results in the formation of short 
glucose polymers that will be ready for elongation through the action of glycogen 
synthase 
(169)
. Glycogen synthase regulation by phosphorylation, which causes a 
reduction in its activity and allosterocally by glucose -6- phosphate concentrations 
(170) (171)
. Insulin causes the phosphorylation of tyrosine-kinase resulting in increased 
expression of glycogen phosphorylase phosphate and a subsequent increase in 




1.7.5. Insulin Counter Regulatory Hormones  
 
The effects of insulin can be countered by hormonal and neural regulation in response 
to hypoglycaemia. Glucagon, cortisol, catecholamines (epinephrine, norepinephrine) 
and growth hormone are antagonistic to insulin actions 
(172)
. Glucagon is a catabolic 
peptide hormone that is secreted in pulses from the pancreatic α-cells in response to 
hypoglycaemia 
(173)
. It antagonises insulin‘s actions by promoting glycogenolysis and 
gluconeogenesis and inhibiting the glyconeogenic processes causing an increase in the 
blood glucose levels. Glucagon secretion is controlled by the α-cells due to its 
sensitivity to high glucose levels mediated via both the parasympathetic and 
sympathetic divisions of the nervous system (sympathoadrenal axis and intra –islet 
insulin) 
(146) (173)
. The autonomic nervous system action due to low blood glucose 
causes glucagon to be released through the activation of β2- adrenoreceptors by 
adrenaline released from the adrenal medulla
 (174) 
. The glucagon receptor is a G-
protein coupled receptor and the activation of the two classes GSα and Gq are an 






of GSα causes 
increased cellular cAMP levels through the actions of adenylate cyclase resulting in 
the activation of protein kinase A (PKA). PKA phosphorylates glycogen 





. On the other hand, the Gq activation results in increased 
intracellular Ca
2+
 levels subsequently decreasing glycolysis 
(175)
. Other pathways 
activated include protein kinase C (PKC) and mitogen-activated protein kinases 
(MAPK) that are pro gluconeogenic 
(175)
. Glycogen down regulates the gene 
expression of pyruvate kinase a key enzyme in the glycolysis cycle resulting in 
increased glucose production.  
1.8.0. Consequences of Chronic Hyperglycaemia 
 
Persistent hyperglycaemia contributes significantly to the development of diabetic 
complications. Several molecular pathways have been proposed in an effort to explain 
the pathological developments of these complications 
(176)
. The biochemical pathways 
involved include the hexosamine pathway, polyol pathway, protein kinase C 
activation, enhanced oxidative pathways, formation of advanced glycation end 
products and activation of the renin-angiotensin system
 (177)
. Accumulation and 
formation and or expression of diacylglycerol (DAG), protein kinase C (PKC)
 (178)
, 
Nuclear Factor -қB (NF-қB) 
(177)
 and reactive oxygen species generation 
(178) 
play a 
major role in the development of diabetic complications. Toxic metabolites produced 
from these pathways have been known to cause altered gene expressions; protein 
functions and cell activating molecules resulting in cell damage.  
1.8.1. Advanced Glycation End Products (AGEs)  
 
AGEs are formed by a non-enzymatic process in which glucose (a reducing sugar) 
reacts with an amine residue on a protein, lipid or nucleic acids to form schiff bases, 
early glycation products and amadori which are reversible intermediate glycation 
products 
(179)
. These products undergo further glycation and oxidation resulting in 





. The AGEs formed from the Amadori (1-amino-1-deoxyketose) 





carboxyethyllysine (CEL) and pentosidine or glycation without 
oxidation forming pyralline 
(179) (182)
.The products formed from the polyol pathway 
namely; 3-deoxyglucosone (3-DG), methylglyoxal and glyoxal cause an increased 
carbonyl stress due to their accumulation and their reaction with certain proteins like 
lysine and arginine or lipids forming CML a major AGE
 (183)
. AGE formation is faster 
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when the reaction takes place between intracellular sugars like glucose-6-phosphate, 
glyceraldehyde-3-phopshate 
(183)
 and fructose because glucose has a slower glycation 
rate
 (179)
. The cellular signalling caused by the AGE is mediated via interaction with 
receptor for advanced glycated end products (RAGE) and RAGE/Lactoferrin like 
polypeptide (LF-L) complex resulting in the activation of different signalling cascades 
(181)
.  
RAGE is a receptor from the immunoglobulin super-family with 3 immunoglobuluin 
like domains located in different tissues
 (179) (181) (184) (185)
. NF-қB, interferon –γ- 
response element and interleukin-6 has been identified on the RAGE promoter 
(183)
. 
Accumulation of AGE and its interaction with RAGE has been linked to the 
development of vascular complications of hyperglycaemia 
(179)
. RAGE stimulation 
has been associated with their constant activation/upregulation 
(184)
. RAGE ligand –
RAGE complex has been linked with beta cell dysfunction in type 1 and type 2 
diabetes
 (158)
. AGE causes the up-regulation of RAGE and generation of ROS via the 
NAD P H oxidase and this in turn causes generation of more AGEs 
(177)
. AGE 
activates various signalling cascades like; MAP kinase, PKC and transcriptional 
factors, which cause cellular dysfunction. AGE can be detected in the serum and 
glomerular tissues and increased levels in these locations are strong indicators of 















 Figure 13: AGE generation form different pathways adapted and modified with 
















Figure 14: Signalling cascade of age mediated effects in diabetic microvasular 
complications adapted from GOH and Cooper 2008 
(180)
. 
1.8.2 The Polyol Pathway  
 
The polyol pathway has also been implicated in the formation of advanced glycation 
end products, activation of PKC and it is also a major source of ROS
 (182)
. During 
hyperglycemia, glucose is metabolised extensively through the polyol pathway 
(186)
. 
Aldose reductase catalyses the conversion of glucose to sorbital and it is the rate 
limiting enzyme in the polyol pathway
 (187)
. Sorbital undergoes oxidation catalysed by 
the enzyme sorbital dehydrogenase (SDH) to form fructose
 (176)
. Through the polyol 
pathway the AGE products formed are; glyoxal, methlyglyoxal (MGO) and 3-
deoxyglucosone (3-DG) and they are α-oxoaldehydes
 (179) 
(Figure 13). In addition to 
formation of AGE, increased concentration of aldose reductase has been associated 
with the development of diabetic neuropathy and inhibition of this enzyme by 
zenarestat ameliorated the situation
 (188)
. Accumulation of sorbital in the tissues has 






. Its accumulation in retinal and or vascular tissues has been associated with the 
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1.8.3. Oxidative stress 
 
Oxidative stress occurs when a cell is chronically exposed to reactive oxygen species
 
(191)
. Reactive oxygen species (ROS) is a term generally used to describe free oxygen 
radicals and non-radical oxidizing agents 
(192). 
Disruption of the redox homeostasis 
process leads to excessive generation of ROS leading to an increase in oxidative 
stress. Factors that upset the negative feedback mechanism of the body that is 
responsible for regulating ROS generation cause increased generation ROS. These 
factors include mitochondrial dysfunction, AGE formation and increased flux in the 
polyol pathway. Glutathione peroxidise-1 located in the mitochondrion is responsible 
for the breakdown of hydrogen peroxide to water. In a dysfunctional mitochondrion, 
hydrogen peroxide is converted to a hydroxyl radical and coupled to an impaired 
electron transport chain leading to increased production in ROS
 (193)
. ROS generation 
from various organs/tissues has been associated with decline in the pancreatic β-cell 
function as observed in type 2 diabetes
 (194)
. Glucose -6-phosphate dehydrogenase 
(G6PD) is the major source of nicotinamide adenine dinucleotide phosphate 
(NADPH) that is responsible for the activation and action of the body‘s enzymatic 
antioxidant systems 
(142)
. NADPH is an important component in the functioning of 
glutathione reductase activity
 (187)
. Zhang et al.
 (142)
 showed that hyperglycaemia 
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causes decreased GSH and ultimately the inhibition G6PD causing increased 
oxidative stress. The balance between ROS generation and stable oxygen species are 
maintained by enzymatic and non-enzymatic antioxidant systems produced in the 
body coupled with consumption of fruits and vegetables that contain flavonoids, 




The redox homeostatic balance can upset the natural antioxidant defence mechanism 
due to disease states. Enzymatic and non-enzymatic processes have been identified in 
the formation of these reactive oxygen species 
(192)
. Kojda and Harrison in their 
review identified 9 enzymatic sources of ROS 
(191)
. Some of the major sources of ROS 
are superoxide released from mitochondria, ―leakage‖ in mitochondrial electron 
transport chain (METC) 
(195)
, membrane bound NADPH oxidase
 (196)
 and 




. The polyol 
pathway causes the generation of ROS through the actions of aldose reductase a 
monomeric oxidoreductase and sorbital dehydrogenase [Figure 15]. The conversion of 
glucose to sorbital leads to the depletion of NADPH and the oxidation of sorbital 
leads conversion of NAD
+




NADPH oxidase catalyses the conversion of NADPH to ROS
 (197)
. There is increasing 
evidence that shows NADPH oxidase plays a major role in the pathophysiology of 
vascular diseases, hypertension, hypercholesterolemia and atherosclerosis
 (197) 
. An 
increase in the NADH/NAD
+
 ratio causes a decrease in nitric oxide (NO) and an 
alteration in the cellular redox, oxidant and osmotic stress 
(198)
. Polyunsaturated fatty 
acids undergo oxidation by oxoferryl species and lead to the formation of peroxyl 
radicals that can cause the oxidation of membrane lipids and proteins leading to the 
formation of more reactive radicals
 (192) (195) 
causing an increase in oxidative stress 
through AGEs formation [Figure14]. 
 
 Activation of transcriptional factors, for example NF-қB by RAGE-AGE interaction 
leads to addition of oxidative pressure on the tissues 
(177)
. A study done by Inoguchi et 
al.
 (197)
 showed that the generation of ROS in renal mesangial cells and vascular 






1.8.4. Protein Kinase C Pathways (PKC) 
 
Protein kinase C (PKC) is a single polypeptide chain containing a regulatory and a 
catalytic region in its structure located in the N-terminal and C-terminal respectively 
(199)
 and is a member of the AGC family of protein kinases
 (200)
. The four domains C1-
C4 are binding sites for different substrates namely C1- Diacylglycerol / phorbol 
esters, C2- anionic lipids in a calcium dependent manner; C3 and C4- ATP and 
substrate binding lobes of kinase cores. The 11 iso-enzymes identified are categorised 
into 3 groups namely the conventional, novel and atypical according to what activates 
the iso-enzymes 
(201)
. The different isoforms of PKC are α, β1, β2, γ, µ, ε, δ, δ, θ, λ, ŋ 
and they are specific to particular cells
 (178) (199) (200)
. The isoforms PKC β1 and β2 are 
obtained from the 47splicing of PKC β gene and it has been shown that these two 
isoform have antagonistic effects. The expression of PKC β1 and β2 in monocytes is 
regulated by insulin in a dose dependent manner by controlling the splicing of the 
parent gene and the expression of PKC β subtypes
 (202)
. PKC isoforms α, β1 and δ are 
increased in glomerular tissues of diabetic rats, α, β2 and ε in the retinal tissues 




Calpains a cytosolic calcium-dependent cysteine protease has also been implicated in 
diabetic vascular dysfunction. A study done by Smolock et al.
 (202) 
revealed that the 
PKC isoform (PKC β ) causes the activation of endothelial expressed calpain which 
causes an increase in cell adhesion molecule (ICAM-1), causing an increased 
leukocyte-endothelium interactions which have been implicated in vascular 
complications 
(198)
. An increase in the NADH: NAD
+
 ratio from increased flux in the 
polyol pathway causes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to be 
inhibited. Its inhibition results in the increase of triose phosphate and consequently 





 and DAG a lipid second messenger causes the activation of the PKC 
pathway 
(203)
. The formation of DAG is dependent on the actions of Phospholipase C. 
This enzyme is located in mammalian tissues and is responsible for hydrolysis of 







The PKC signal cascade can starts from the reduction of dihydroxyacetone phosphate 





In vivo and in vitro studies show that chronic hyperglycaemia creates an 
internal environment that is conducive for DAG formation leading to sustained 
activation of PKC resulting in vascular complications 
(176) (197)
. The activation of PKC 
via different pathways causes specific changes in various tissues and alteration of 
function in certain enzymes. PKC activation causes an increases in tissue 
permeability, expansion of extracellular matrix, thickening of the basement 





ATPase and transcription factors 
(201)
. Endothelial dysfunction is accompanied by a 
decreased production of prostacyclin, nitric oxide (NO) that is responsible for 
maintaining blood vessel integrity and an increase in endothelin-1, vascular 
endothelial growth factor and cyclooxygenase dependent vasoconstrictors
 (198) (201)
. 
The inhibition of the DAG-PKC pathway by PKC specific isoform inhibitor 
ruboxistaurin mesylate improves haemodynamic changes in nephropathy, retinopathy 
and neuropathy 
(205) 
thus ameliorating the detrimental effects mediated by the 
activation and action of Protein Kinase C. 
1.9.0. Diabetic complications  
 
Metabolic and haemodynamic factors intertwined together in diabetic patients are 
associated with the development of cardiovascular diseases, stroke, atherosclerosis, 
nephropathy, neuropathy and retinopathy
 (206)
. These complications can be categorised 
into two major groups namely macrovascular and microvascular complications.  
1.9.1 Microvascular Complications  
1.9.1.1. Diabetic Neuropathy  
 
Diabetic neuropathy is a disorder of the peripheral nervous and autonomic nervous 
system as well as some cranial nerves due to chronic effects of hyperglycaemia 
(207)
. 
This neurological complication affects both type 1 and type 2 diabetic patients with 
long standing diabetes
 (188)
. Diabetic neuropathy is the leading cause of non-traumatic 
amputations, ulcers that take long to heal and nerve injury 
(176). 
There are different 
types of neuropathies and they are be classified as symmetric and asymmetric with 
their clinical manifestations dependent on the group of nerves affected. The aetiology 
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of diabetic neuropathy is not well understood but it is believed that, the formation of 
AGE, increased oxidative stress, increased polyol pathway and diabetic vascular 
disease play a pivotal role in the progression of the disease 
(188)
. It is characterised by 
segmental demyelination accompanied by loss of myelinated and unmyelinated axons 
(208)
. It is speculated that hyperglycaemia causes the depletion of neurotrophins that 
are responsible for normal axon repair 
(188)
 and the progression of the complication by 
AGE has been shown to cause a decrease in the sensorimotor conduction velocity and 
reduced blood flow in peripheral tissues 
(156)
. Treatment with aldose reductase 
inhibitor fidareplast improves nerve conductance velocity and palrestat can delay the 
progression of the disease and ameliorates the associated symptoms 
(176)
.  
1.9.1.2. Diabetic Retinopathy  
 
Retinopathy is the major cause of blindness in diabetic patients. Biochemical 
pathways involved in the pathophysiological development of diabetic retinopathy 
have since been identified. The retinal changes associated with diabetic retinopathy 
are haemorrhages, microaneurysms and proliferative retinopathy 
(207)
. The earliest 
morphological changes that can be seen are loss of pericytes and a cellular capillary 
formation 
(188)
. In the retinal tissues of diabetic subjects there is an increased 
accumulation of DAG and a consequent activation of PKC 
(176) 
isoform β that causes 
increased vascular permeability and formation of microaneurisms and the PKC δ 
causes retinal pericyte apoptosis through the activation of NF-қB
 (176) (201)
. These 
changes cause glaucoma and cataracts and if not treaded could lead to total blindness. 
1.9.2 Macrovascular Complications  
1.9.2.1. Atherosclerosis  
 
Diabetes is a major risk factor associated with the development of stroke, coronary 
heart disease, peripheral artery disease and atherosclerosis 
[211]
. Atherosclerosis and 
thrombogenic complications are a major cause of morbidity and premature death in 
diabetic patients 
(208)
. Multiple independent pathways discussed previously have been 
implicated in the development and pathological progression of atherosclerosis. In 
diabetic patients with atherosclerosis, dyslipidaemia is characterized with high levels 
of low density lipoprotein (LDL) and very low density lipoprotein (VLDL) and 
decreased high density lipoproteins (HDL) 
(39)
. Increased levels of glycation and lipid 
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peroxidation products in diabetic patients especially apoprotein B and phospholipid 
portion of LDL have been associated with alterations of LDL clearance and oxidative 
modifications. AGE binding to Apo B impairs its clearance in the hepatic tissues and 
enhances the retention of LDL accumulation on the aortic wall resulting in an 




Increased expression of RAGE in the human atherosclerotic plaques is co-localised 
with cyclooxygenase 2, microsomal prostaglandin E2 which causes destabilization of 
the plaques via the action of vascular dependent matrix metalloproteinase-2 which 
cause excessive break down of ECM resulting in plaque rapture 
(209)
. Pharmacological 
agents aminoguanidine and alagebrium have been identified as inhibitors of AGE and 
RAGE expression minimizing the expression of prosclerotic growth factors in 
experimental animals but further studies need to be conducted on them 
(180)
. Intensive 
therapy with HMG CoA reductase inhibitors have proven to be beneficial agents in 
preventing adverse effects associated with lipid peroxidation and lipid modifications 




1.9.2.2. Diabetic Nephropathy  
 
Diabetic nephropathy (DN) is a common microvascular complication associated with 
diabetes mellitus and is the leading cause of end stage renal disease globally (ESRD) 
(177) (184) 
. Epidemiological data estimates that 30-40% of patients with type 2 diabetes 
and 15-20% of type 1 diabetics will develop chronic renal failure 
(176) (211) 
.The risk of 
developing nephropathy is increased in genetically predisposed diabetic patients with 
uncontrolled hyperglycaemia. DN is characterised by the presence of protein in the 
urine, elevated blood pressure
 (212)
 and progressive renal insufficiency 
(189)
 due to 
glomerular lesions and loss of glomerular filtration rate in the absence of albuminuria 
(213)
. The different stages of DN are determined by the extent of renal impairment and 
presence of albuminuria 
(214)
. The uniferous system plays a fundamental role in the 
glucose homeostatic processes, because of sodium glucose co-transporters (SGLT) 
located on the renal proximal tubules (PCT) brush border that is responsible for the 
reabsorption of glucose from the glomerular ultra-filtrate 
(215) (216) (217) (218)  
. This 
hexose carrier protein is also localised in the intestinal lumen where it aids in glucose 





renal cortex also plays a part in increasing the body‘s glucose load (Figure16) 
(219) 
. 
SGLT1 and SGLT2 are expressed in different portions of the PCT and are responsible 
for the reabsorption of glucose coupled with sodium across a concentration gradient 
into the tubules. GLUT1 and GLUT 2 aid its movement across the interstitium back 
into the systemic circulation (Figure 17) 
(219)
. The functioning of these transport 
proteins is augmented by the activity of Sodium/Potassium-ATPase pump on the 
basolateral membrane. In the diabetic state the glucose threshold in the PCT is 
increased from 350 mg/min (normal) to 420 mg/min coupled with increased 
expression of SGLT2 
(220)
. Increased expression of the SGLT2 in PCT causes a 
significant increase of glucose reabsorption resulting in increased hyperglycaemia that 
causes metabolic and haemodynamic changes which impact greatly in the 
pathogenesis on DN. Phytochemicals like naringenin found in many citrus fruits have 
shown potential as potent SGLT2 inhibitors in intestinal and renal cortical brush 
border membrane vesicles in rabbit and rat tissues
 (80)
. This effect could prove 
beneficial in the regulation of blood glucose in type 2 diabetic patients but its effects 







































Figure 17: Glucose movement in the S1 and S3 portions of the proximal  




Chronic hyperglycaemia on renal tissues has detrimental effects to the normal 
functioning of the kidney and subsequent decline in the kidney functions. Structural 
changes in the renal corpuscle and surrounding tissues as a result of metabolic and 
haemodynamic effects induced by hyperglycaemia are implicated in development of 
renal injury and subsequent dysfunction. Molecules like monocyte chemoattractant 
protein-1(MCP-1),intracellular adhesion molecule -1(ICAM-1), cyclooxygenase 2 
(COX-2) , nitric oxide synthase, vascular endothelial growth factor (VEGF), 
transforming growth factor β , nuclear factor қβ (NF- қβ) and inflammatory cytokines 





1.9.2.3. Pathological Development of Diabetic Nephropathy  
 
In DN, thickening of the glomerular basement membrane (GBM) highlighted in green 
(Figure 18) is accompanied by mesangial expansion, thickening due to fibrosis and 
expansion of tubulo-intestitial compartments due to increased extracellular matrix 
deposition
 (198) (222)
. In the progression of DN glomerular sclerosis, arteriolar 
hyalinosis, and tubulo-interstitial remodelling are the pathological features observed 
in the advanced stages 
(223)
. Mesangial cells located in the glomerulus are responsible 
for the synthesis of extracellular matrix (ECM) and accumulation of the ECM is a 
major problem that results in alteration of the renal structures. Matrix 
metalloproteases (MMP) are zinc dependent endopeptidases responsible for the 
degradation and physiological regulation of ECM but in the diabetic state their 




The kidney is the major site for AGE clearance and its dysfunction contributes to 
increased accumulation of AGE. AGE accumulation plays an active role in the 
impairment of the renal functions because of its direct effects on matrix 





reactive oxygen species and transforming growth factor β (TGF-β)
 (225) 
trigger the 
expression of TGF-β and connective tissue growth factor (CTGF/ CCN2) which 
contribute to ECM thickening. The actions of CTGF are diverse but they all 
contribute to the process of fibrosis by fuelling the production of the protein 
fibronectin and plasminogen activator inhibitor synthesis
 (225)
. Increased expression of 
urinary CTGF (uCTGT) has been shown as an important biomarker in the assessment 
of tubular function because CTGF is fully reabsorbed in the PCT and increased 
uCTGF has been observed in patients with DN 
(226) 
. In addition, Cell division 
autoantigen 1 (CDA1) an antiproliferative, Angiotensin Converting Enzyme II (ACE 
II) and profibrotic growth factor similar to TGF-β also contribute to these renal 
changes 
(214)
. Vascular remodelling due to increased ECM deposition results in the 
crushing of glomerular capillaries which in-turn compromises the glomerular 

































Figure 18: Schematic organization of the renal corpuscle adapted and modified with permission from 
Ross and Pawlina (256) 
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Glomerular hypertension, hyperfiltration and endothelial dysfunction are some of the 
haemodynamic factors that have been associated with a decrease in NO and an increase in 
ACE II in DN. Angiotensin converting enzyme (ACE) in the kidney catalyses the conversion 
of angiotensin I to angiotensin II . It has been reported that Angiotensin II plays a major role 
in the progression of DN by adding to the haemodynamic and structural changes 
(214)
. Some 
of the effects of ACE II are mediated via increasing the synthesis of plasminogen activator 
inhibitor -1(PAI-1) 
[267]
, activation of transforming Growth factor β (TGF-β) and Smad3 
(227)
. 
Smads are cytoplasmic proteins that are substrates for type 1 TGF β receptors
 (228)
. Activation 
of pro-sclerotic cytokines like TGF-β by hyperglycaemia at the transcriptional level, and 
angiotensin II advance the progression of DN by promoting matrix production and inhibiting 
their degradation while increasing the matrix receptors 
(219)
. These changes modify the cell 
structure and function resulting in defective cell adhesion and altered cell growth 
(229)
. Studies 
have confirmed an increased expression of TGF-β in renal tissues of diabetic animals and 
administration of TGF-β inhibitors such as CTGF-antisense oligonucleotide or CTGF-
siRNA, ACE inhibitors and angiotensin receptor blockers ameliorate the detrimental effects 
of TGF-β thus conferring renoprotection
(68)
. Increased expression of endothelin-1, 





Inflammatory processes also play a major role in the development and progression of DN. 
The binding of AGE to its receptor (RAGE) in the renal tubules results in the formation of 
myofibroblasts and this process is implicated in tubular atrophy and interstitial fibrosis 
(229) 
. 
In addition, AGE/RAGE interactions cause the activation and/or expression of inflammatory 
mediators that contribute to vascular dysfunction 
(177) (213)
. TNF-α has been implicated in the 
development of glomerular insulin resistance, reduction in the glomerular filtration rate, local 
generation of ROS and production of endothelin-1 resulting in organ dysfunction. Increased 
RAGE expression in vascular tissues of diabetic patients triggers the expression of adhesion 
molecules like vascular cell adhesion molecule- 1(VCAM-1), IL-6, MCP-1and generation of 
ROS
 (182)
. This is accompanied by increased glomerular deposition of AGE on the capillaries 
which lead to the expression of VEGF, VEGF receptor and RAGE. VEGF expression results 
in increased vascular fenestrations at the glomerular endothelial brush border resulting in 
capillary basement modification. These fenestrations allow large molecules like albumin to 
pass through and be excreted in urine resulting in albuminuria, a characteristic feature in DN 
(182) 
Treatment with VEGF receptor -2 antibodies and soluble RAGE (sRAGE) improved 
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glomerular hypertrophy and albuminuria in diabetic db/db mice (182) . In addition, the 
expression of NF-қB, a transcriptional factor located on the RAGE promoter and early 
growth response 1(Egr-1) have been implicated in the inflammatory processes that take place 
in the kidney. Increased expression of NF-ĸB causes pro-inflammatory cytokines like IL-1 α, 
IL-6, TNF-α to be expressed with PKC contributing significantly to renal inflammatory 
processes, 
(179)
 which cause serious tubular inflammation and cell proliferation that contribute 






 and adrenocorticotropic hormone (ACTH) stimulate the expression of 






and water balance in the 
renal tubules. Aldosterone works by stimulating Na
+













. Increased expression of aldosterone 
is characterised by increased inflammation and matrix accumulation 
(230)
. Mineralcorticoid 
receptors on the glomerular mesangial cells mediate the actions of aldosterone and this causes 
proliferation and increase in ROS generation in SGK1
 (230)
. In vivo and in vitro results hae 
shown that treatment with spirolactone down-regulates the expression of VEGF, insulin 




In the late stages of DN, reduced GFR is accompanied by increased Na
+
 retention in patients 
suffering from diabetes mellitus. Na
+
 retention can plays a major role in the development of 
arterial hypertension 
(232)
. Altered ion transport in the PCT as a result of hypertrophy due to 
effects of CTGF and tubular atrophy play a major role on DN progression. IGF-1 has been 
implicated in the increased retention of Na
+
 in diabetic patients. Its receptors are located in 
the glomerulus and tubular segments in the apical and basolateral membranes. Vascular 
permeability due to increased fenestrations causes the IGF-I from the plasma to be filtered 
through the glomerulus. The ultrafiltrate containing IGF-I enhance Na
+
 transport in the distal 






In addition elevated levels of insulin have been known to cause stimulation of sodium 
reabsorption in the DCT due to its antinatriuresis effects 
(234)
. The reabsorption of Na
+ 
along 
the nephrons is controlled by different regulators and inhibition of these regulators can result 
in altered sodium concentrations (Table 8). Elevated plasma levels of D-glucose and or IL-1β 
causes an increase in hyaluronic acid (HA) in injured proximal tubule. HA has been known to 
induce the up-regulation of ICAM-1, VCAM-1 and chemoattractant protein 1 expression 
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which contributes to the progression of diabetic nephropathy 
(235) (236)
. In the tubular 
endothelium myo-inositol oxygenase (MIOX) is responsible for the oxidation of Myo- 
inositol that is generated from Glucose -6- phosphate. Its metabolic product 
phosphatidylinositol has osmoregulatory function in the kidney. Up regulation of MIOX in 
diabetic animals and supplementation normalizes ―glucose-induced proliferation and collagen 
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Table 8: Percentage of Na
+




1.9.3. Diabetes Management  
 
The current approach used in the management of type 2 diabetes mellitus involves the 
adoption of a healthy lifestyle which includes weight control, physical exercise, and proper 
nutrition in combination with pharmacological therapy in order to prevent the development 




1.9.4. Pharmacotherapy of Diabetes 
1.9.4.1 Insulin Therapy  
 
Type 1 diabetes is managed by the use of exogenous insulin to lower the blood glucose levels 
and to prevent development of diabetic ketoacidosis (DKA) 
(78) (110)  (111)
. There are 4 main 
types of insulin available in the market today i.e.: rapid acting with fast onset but short 
duration (Insulin lispro and aspart), short acting with  rapid onset of action (humulin  and 
novolin R, L and N ) intermediate acting (Lente insulin, glargine and NPH insulin) and long 
acting (ultralente humulin and insulin glargine-  lantus) 
(238)
. Insulin therapy can also be 
introduced to patients with type 2 diabetes who are already on oral hypoglycaemic agents. 
The addition of insulin to the treatment regimen helps to lower the blood glucose 
concentration and reduce adverse effects associated with chronic hyperglycaemia. There are 
limitations associated with the use of exogenous insulin. One of the major problems is the 
high incidence of iatrogenic hypoglycaemia associated with their use. At least 90 % of type 1 
diabetics have experienced a hypoglycaemic episode and this can be fatal 
(172) (239)
. The other 
dilemma is pain associated with repeated injections at the same site and improper storage that 




In addition to hypoglycaemia and pain, 
weight gain due to reduced calorie leakage into urine and increased appetite can make 
patients skip dosages with the resultant effect of poor glycaemia control 
(241)
.  
1.9.4.2 Oral Hypoglycaemic  
 
In type 2 diabetes, the pancreatic β-cell is dysfunctional but can still produce insulin that is 
not sufficient to maintain euglycaemia. Pharmacological management is by the use of oral 
hypoglycaemic agents and in severe cases in combination with exogenous insulin 
(242)
. There 
are 5 main classes of oral hypoglycaemic agents available in the market (Table 9). They can 
be categorised as insulin sensitizers, insulin secretagogues and inctretin based therapies.  
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a) Insulin secretagogues  
 
Meglitidines, sulfonylurea and D-phenyl alnanine derivatives increase the secretion of insulin 
from the pancreatic β-cells. This is because the sulfonylurea receptor is located on the ATP 
sensitive K
+ 
channel on the pancreatic β-cell. Binding of sulfonylurea to the sulfonylurea 
receptor -1(SUR-1) causes decreased influx of K
+ 
leading to depolarization of the voltage 
sensitive calcium channel resulting in insulin secretion 
(200)
. Meglitidines on the other hand 
are non-sulfonylureas but act in a similar manner to sulfonylureas. The problem associated 
with their use is the incidence of hypoglycaemia, increased cardiac arrhythmias because of its 
activity on SUR2 in vascular and cardiac tissues
 (116)
. The use of sulfonylureas alone is not 
sufficient to maintain the desired glycaemic control and a second hypoglycaemic agent 
sometimes is required 
(243)
. Secondary failure associated with the use of sulfonylureas can be 
due to reduced glomerular filtration rate casing an increased risk of hypoglycaemia, insulin 
resistance
 (238)
 and β-cell destruction leading to decreased insulin production and 
consequently therapy failure.  
b) Insulin sensitizers  
 
Metformin is a biguanide that has been used since the 1950s to manage hyperglycaemia and 
it is currently the first line treatment for type 2 diabetes. Metformin improves insulin 
sensitivity in hepatic and peripheral tissues and is beneficial in patients suffering from IR 
(228)
. In the skeletal muscles it causes increased translocation of GLUT-4 and the activity of 
insulin receptor tyrosine kinase this causes an increase in glucose uptake
 (228) (243)
. In addition, 
it stimulates glycolysis and reduces the gluconeogenesis process in the skeletal and hepatic 
tissues 
(238)
. Though it manages to lower blood glucose levels significantly, it causes minor 
gastrointestinal disturbances (diarrhoea, nausea, vomiting and abdominal discomfort) and 
lactic acidosis
 (135) (144)
. Metformin is currently contraindicated in diabetic patients suffering 
from renal disease /dysfunction, cardiac insufficiency, DKA because of the increased risk of 




Thizolidinediones work by binding to the nuclear transcription factors peroxisome 
proliferator activated receptor γ (PPARγ). They improve insulin sensitivity in the peripheral 
tissues by promoting the uptake of free fatty acids in subcutaneous adipose tissue
 (238) 
. The 
binding with the PPARγ causes increased expression of GLUT2 and GLUT4 and subsequent 
increase in glucose uptake from the circulatory system 
(228)
. They reduce plasma triglyceride 
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levels and increase HDL – cholesterol and LDL- levels with increased LDL- levels being an 
undesirable effect 
(243)
. The adverse effects associated with their use are weight gain, 




c) α-glucosidase Inhibitors 
 
α–amylase and α–glucosidase are intestinal brush border enzymes that metabolize 
carbohydrates (oligosaccharides and polysaccharides) 
(102) (228)
. α- glucosidase inhibitors work 
by preventing the breakdown of complex carbohydrates by inhibition of the α- glucosidase 
enzymes reducing the entry of glucose into the systemic circulation thus preventing post 
prandial hyperglycaemia (PPH). The side effects associated with their use is diarrhoea, 
bloating and flatulence 
(228) (238)
. The advantage of α- glucosidase inhibitors use is that the 
incidence of hypoglycaemia and weight gain are greatly reduced 
(243)
.   
d) Incretin Based therapy  
 
Glucagon like peptide -1(GLP-1) and glucose dependent insulinotropic peptide (GIP) are the 





The protease dipeptidyl-peptidase IV (DPP-4) acts on the GLP-1 degrading it after a short 
period rendering it pharmacologically inert but the development of DPP-4 inhibitors 
(Sitaglipin) increases GLP-1‘s half-life rendering it useful in the management of 
hyperglycaemia 
(244)
. The production of GLP-1 mimetics (Exenatide) proved to be a great 




. GLP-1 stimulates the release of insulin from the pancreatic β-cells. This stimulation 
is dependent on the physiological concentration of glucose. This effect is important because it 
helps reduce the incidences of hypoglycaemia 
(245)
 and the inhibition of glucagon secretion 
and gastric emptying delay helps reduce incidences of postprandial hyperglycaemia 
(228)
. 
Incretin based therapy is slowly gaining popularity in clinical practice because of its glucose 
dependent insulin secretion and inhibition of glucagon secretion. Other agents that are still 
undergoing clinical trials (stage III) include SGLT2 inhibitors such as dapagliflozin, 
remogliflozin, etabonate, sergliflozin and AVE2268. These agents inhibit sodium –glucose 
co-transporters responsible for re-absorption of glucose in the renal tissues and researchers 








1st generation *, 2nd generation** 
 
 
The number of hypoglycaemic agents has increased significantly over the years with 
development and discovery of new agents. The complex pathophysiology and co-morbidities 
associated with type 2 diabetes makes monotherapy with the available agents ineffective
 (122)
. 
To manage hyperglycaemia and the related complications, multiple therapeutic agents are 
used and this can be very costly and cumbersome because of the associated side effects. 
Insulin sensitizer‘s metformin and TZDs manage to reduce the risk factors associated with 
development of cardiovascular diseases in diabetic patients but the use of metformin is 
contraindicated in patients with renal insufficiency 
(247)
. The management of diabetic 
nephropathy currently is limited to therapies that block the rennin-angiotensin - aldosterone- 
system (RAAS)
 (212)
. ACE inhibitors, Angiotensin receptor blockers (ARB) and aldosterone 
antagonists are antihypertensive agents that work on the RAAS conferring renoprotection by 
helping prevent the initiation of diabetic nephropathy in type 1 and type 2 diabetic patients
 
(212)
. In some cases where the disease has progressed ARB or ACE inhibitors do not slow 
down or prevent the development of ESRD requiring other interventions. Other agents under 
investigation are AGE/RAGE inhibitors, PKC inhibitors and TGF-β inhibitors are in progress 
but their safety and efficacy in diabetic patients is yet to be established. The complex 


























Repaglinide, Nateglinide Increase insulin secretion 
α-glucosidase inhibitiors (AGIs) Acarbose, Miglitol, voglibose 
 
Inhibits intestinal digestion 
Of polysaccharides 
Thiazolidinedines (TZD) Pioglitazone, Rosiglitazone, 
 
Express transcription factors 
promoting insulin sensitivity, 
secretion 
 




Table 9: Classes of oral anti-diabetic agents  
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for new treatment interventions that would help prevent progression of DN and development 
of ESRD.  
1.9.5. Basis of Study  
 
Grapefruit in particular has gained much recognition because of its beneficial medicinal 
effects and weight loss properties. Recent studies have shown that the consumption of GFJ 
helps to improve blood glucose levels, ameliorates diabetic dyslipidaemia 
(39)
, damage caused 
by free radicals in diabetic tissues 
(38) (46) 
and helps improve metabolic syndrome
 (25)
. Evidence 
from our laboratory shows that STZ-induced diabetic rats and non-diabetic rats treated with 
GFJ experienced increased polydipsia suggesting increased salt-water excretion by the kidney 
(39)
. Naringin a bioactive component in GFJ inhibits glucose transporters in the renal tissues
 
(80) 
while naringenin possesses anti-inflammatory and anti-fibrotic effects in diabetic mice 
(234)
. GFJ has a high concentration of naringin but very little is known about its effect on fluid 
and electrolyte homeostasis. This study was aimed at investigating the effect of GFJ on renal 
dysfunction and hyperglycaemia in STZ-induced diabetic male wistar rats. 
1.9.5.1 Hypothesis  
 
Ruby Grapefruit juice (Citrus Paradisi MACF., FAMILY Rutacaeae) possesses anti- 
hyperglycaemic and renoprotective effects in STZ-induced diabetic rats. 




The aim of this study was to investigate the effect of GFJ on glucose homeostasis and renal 




1. To investigate the effects of chronic administration of GFJ on glucose intolerance in 
STZ- induced diabetic rats. 




Chapter 2  
Materials and Methods 
2.0. Materials  
Chemical Reagents  
 
The chemical reagents used in this study were purchased from Sigma –Aldrich Pty. LTD., 
Johannesburg South Africa are: D-glucose, streptozotocin, citrate (C6H8O7), phosphate 
buffers, glycogen from oyster, sulphuric acid (H2SO4), potassium hydroxide (KOH), ethanol, 
phenol and sodium sulphate, haemotoxylin, potassium alum, citric acid, chloral hydrate 
,sodium Iodate, concentrated hydrochloric acid (HCl), celestine blue B, ferric ammonium 
sulphate, glycerin, acid fuschin, glacial acetic acid, phosohomolybdic acid and methyl blue . 
 
From the local pharmacy, the following agents were purchased: insulin, normal saline (0.9% 
NaCl), portable glucometer and glucose test strips (Ascensia Elite
TM
 Bayer AG., Leverkusen, 
Germany).The Biochemical Research Unit of the University of KwaZulu-Natal, Durban 
South Africa provided Fluorothane® (Halothane) AstraZeneca Pharmaceuticals, South 
Africa.  
 
Grapefruit: Ruby grapefruit juice was purchased from a Woolworths Groceries store located 
in Durban, South Africa. The nutritive value of the grapefruit juice as per the labelling are: 
contents per 100 ml: Energy 190 Kj; Protein, 0.6 g; Carbohydrate, 10.0 g; Total fat ,0.0 g; 
Total dietary fibre ,0.4 g; Sodium 0.0 g. The fruit juice contains no preservatives or food 
additives as per manufacturer‘s declaration.  
Equipment used  
 The Nikon Compound Light Microscope attached to a computer  
 Freezer (Mallkinckrodt, Ohio, USA) 
 Beckman Coulter (Synchron LX20 Clinical Systems, Fullerton, California, USA) 
 Makrolon polycarbonate metabolic cages (Techniplats, Labotec, South Africa) 




2.1 Study Design and Procedure  
2.1.1 Animal Treatment  
 
Ethical Approval 
The experimental procedures and protocol applied in this study were approved by University 
of KwaZulu-Natal Animal Ethics Research committee and conforms to the ―Guide to the 
care and used of laboratory animals in research and teaching‖. [Published by university of 
KwaZulu-Natal ethics committee] . Ethics number: 084/11/animal (Ethics approval attached 
in appendix 1) 
2.1.2 Animal Treatment Procedure 
 
56 male Rattus novergicus (Wistar rats) that weighed between 250-300 g were obtained and 
housed at the Biomedical Research Unit (BRU) located at the University of KwaZulu-Natal 
Westville campus. The animals were divided into two major groups (Diabetic and non-
diabetic) with 7 subgroups containing 7 animals per cage. Laboratory conditions of 12 Hour 
light/dark cycle from 08H00-20H00, temperature 25±2
0
C and humidity 55±5% were 
maintained throughout the study period. The animals were allowed free access to commercial 
rat chow and water ad libitum. The different groups were treated with distilled water or 
regular insulin or grapefruit juice for a period of 8 weeks. 
The non-diabetic animals, group 1 (Control) were treated orally with 1.0 ml /Kg BW of 
distilled water while group 2 (ND-GFJ) were treated orally with 3.0 ml /kg BW of GFJ. The 
diabetic animals, groups 3, 4, 5 6 and 7 were starved overnight in preparation for the 45 
mg/Kg BW or 60 mg/Kg BW of STZ injection. STZ was dissolved in 0.2 ml of 0.1 M Citrate 
buffer at pH 4.5. Groups 3, 4 and 7 received 60.0 mg/ Kg BW of STZ while groups 5 and 6 
received 45mg/kg  BW of STZ. Fasting blood glucose concentrations were obtained via tail 
prick before STZ was administered via a single injection into the peritoneal cavity. Following 
STZ induction, the diabetic state was confirmed after 3 days by obtaining blood via a tail 
prick. Animals with fasting blood glucose greater than 6 mmol/L were selected for the study 
(39)
. Group 4 (INS- D60) and group 5 (INS- D45) were further treated with 4.0 U/kg BW of 
insulin by subcutaneous injection (S.C) twice a day while group 3 (D-60) was treated with 
1.0 ml /Kg BW of distilled water, Group 6 (GFJ-D45) and group 7 (GFJ-D60) were treated 




Table 10:  Animal Treatment Protocol 
On day 57, the rats from each group were housed individually in a Makrolon polycarbonate 
metabolic cages (Techniplats, Labotec, South Africa) for a period of 24 hours (20H00- 
08h00). The animals were allowed free access to water ad libitum and standard rat chow .The 
urine was collected for a period of 24 hours in a calibrated reservoir to enable volume 
determination. The urine samples were stored in a plastic polytops and frozen at -20
o
C before 
analysis. Fasting blood glucose (FBG) and glucose tolerance test (GTT) were done on days 1 
and 59 respectively in all the treatment groups. Water consumption was monitored on a daily 
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days (8weeks) and the final weight for each animal was recorded before the animals were 
sacrificed by halothane overdose (100 mg/kg). Blood samples were obtained via cardiac 
puncture while kidney and liver tissues were excised for further analysis. The kidney and the 
liver were excised from the surrounding connective tissues. The kidney was preserved in 
formalin and the livers were snap frozen in liquid nitrogen and stored at - 80
o
C in a freezer 
(Mallkinckrodt, Ohio, USA) until the day for analysis. This procedure was performed at the 





Chapter 3  
3.0. Methods  
 
3.1. Glucose Tolerance Test 
 
The animals were starved overnight and a fasting blood glucose measurement was taken for 
baseline values. Glucose dissolved in normal saline 3.0g/Kg was administered 
intraperitoneally in all the treatment groups. The blood glucose levels were monitored by 
testing the blood obtained via tail prick at times 0, 15, 30, 60 and 90 minutes. The blood was 
analysed using a portable glucometer and recommended glucose test strips.  
3.2. Electrolyte Analysis 
 
The Beckman Coulter machine was first primed before the samples were analysed. Urine 
samples were thawed at room temperature and a micropipette was used to draw the samples 






), creatinine were analysed 
using the Beckman Coulter (Synchron LX20 Clinical Systems, Fullerton, California, USA). 
The estimation of urea involved the hydrolytic degradation of urea in the presence of urease 
and creatinine determination depended on the reaction of creatinine and sodium picrate to 
form creatinine picrate. The reagent kits used were purchased from Beckman Coulter, 
Dublin, Ireland, Inc.  
3.3. Liver Glycogen Determination 
 
Hepatic glycogen concentration method was adopted and modified from Ong and Khoo 
(2000) methodology 
(248)
. Liver tissue samples weighing between 0.5-1.0 g were placed in a 
pyrex test tube. A volume of 1.5 ml of 30% potassium hydroxide saturated in sodium 
sulphate was added into the test tube to enable homogenization and boiled in a water bath 
(100
0
C) for 20 minutes. The samples were then cooled inside an ice box. Then 2.0 ml of 95% 
ethanol was added to each sample to deproteinize it. The sample was then left to stand on ice 
for approximately 30 minutes. The mixture was then centrifuged for 20 minutes at 840 rpm. 
The supernatant was aspirated and the white precipitate (glycogen) that remained in the tube, 
1000 µL of water was added to it. A volume of 100 µl of dissolved glycogen was then taken 
in triplicate and added onto the test tube then 900 µL of water was added. A volume of 1.0 ml 
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of 5% phenol was added to all test tubes. Then 5 ml of 98% sulphuric acid was added after 30 
seconds and left to stand for 10 minutes then shaken at room temperature for a further 10 
minutes. The mixture was then added onto a cuvet and placed into a Novaspec II 
spectrophotometer (Biochrom Ltd., Cambridge, England) and a reading was taken at 490nm. 
A standard glycogen stock solution was prepared using glycogen powder and it received the 
same treatment as the tissue samples. From this a standard curve was drawn at it was used to 
determine the glycogen concentrations (1mg/ml-1µg/ml) in samples. Blank samples were 
made by replacing the sample with 2 µL of distilled water. 
3.4. Plasma Insulin 
 
Blood collected from heparin containing vacutainer was centrifuged at room temperature for 
20 minutes at 15000rpm. The method of plasma insulin analysis was based on a direct 
sandwich with two monoclonal antibodies that are directed against separate antigenic 
determinants on the insulin molecules. The insulin molecule reacts with peroxidase-
conjugated anti-insulin antibodies that bind to microtitre wells on incubation. The enzymes 
that were unbound were removed by washing while the bound conjugates were detected by 
reaction with 3, 3‘, 5, 5‘-tetramethylbenzidine. 0.5 M Sulphuric acid was added to stop the 
reaction and the resultant coloured product was analysed spectrophotometrically at a 
wavelength of 450nm. 
3.5. Tissues Preparation and Staining   
 
The renal tissue was cut sagittally using a microtome with each section 2µm thick. The 
sections were then mounted onto a microscope slide after being unfolded in a warm water 
bath. The microscopes slides were then heated to ensure proper adhesion of the tissue onto 
the slide. The microscopic slides were stained using Hemotoxylin and Eosin (H&E) and 
Masson‘s Trichrome Stain (MTS). Each slide was stained using both stains. The reagents and 
protocol for the staining procedures are outlined in appendix 2. 
3.5.1 Image Analysis  
 
The stained slides were viewed using The Nikon Compound Light Microscope at the 
University of KwaZulu-Natal‘s Electron Microscope Unit (EMU) equipped with a camera for 
image capture. The images were then analyzed by a pathologist. 
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3.6. Calculations  
 
To determine the Glomerular filtration rate (GFR) the  urinary  clearance of creatinine  and 










3.7. Statistical Analysis 
 
The baseline values were obtained from untreated non-diabetic and STZ-Induced diabetic 
rats. Data obtained will be presented as mean ±SD. Statistical analysis was done by One-way 
ANOVA or non-parametric Mann Whitney V, Student‘s t-test, where applicable, using 
Graphpad Prism
®
, V5.0 (Graphpad Prism
® 
Software, Inc. San Diego CA). A probability level 
of P <0.05 was considered to be statistically significant. 
  
Creatinine clearance (ml/min) = urinary Creatinine (mmol/L) x urine volume (ml) 
                  Plasma Creatinine (mmol/L) 
Area under the curve (AUC) = Calculated from glucose–time curves presented as  








4.1 Animal Growth and Water Consumption 
 
 After the induction of diabetes the weights of the animals changed significantly with diabetic 
animals (D-60 &D-45) exhibiting significant (*P<0.0001) loss in body mass when compared 
to the control. Treatment with GFJ significantly (
Ω
P=0.0020) improved the body mass in 
diabetic group GFJ-D60 when compared to group D-60. In the type 2 diabetic models (GFJ-
D45 vs D45) treatment with GFJ improved the weight but the difference was not statistically 
significant. GFJ treatment did not affect the growth of non-diabetic animals (GFJ-ND) when 
compared to the control (Figure 19). Similarly treatment with insulin (INS-D60) significantly 
(^P <0.0001) improved weight of the diabetic animals when compared to non-treated diabetic 






















































Figure19: Animal growth at the end of 8 weeks of treatment. INS-60, insulin- diabetic 60mg 
STZ;  GFJ- ND, Grapefruit juice non-diabetic; GFJ-D45, Grapefruit juice -diabetic 45mg 
STZ ; GFJ-D60, Grapefruit juice diabetic 60mg STZ;  D-45 , diabetic – 45mg STZ; D-60 , 









Figure 20: Average daily water consumption in treatment groups. INS-60, insulin- diabetic 
60mg STZ; GFJ- ND, Grapefruit juice non-diabetic; GFJ-D45, Grapefruit juice -diabetic 
45mg STZ ; GFJ-D60, Grapefruit juice diabetic 60mg STZ;  D-45 , diabetic – 45mg STZ; D-




The diabetic animals (D-45 and D-60) exhibited significantly (
*
P<0.0001) increased water 
consumption when compared to the control (Figure 20). Treatment of the diabetic animals 
(GFJ-D60) with GFJ reduced the water consumption significantly (
π
P<0.0001) compared to 
the non-treated diabetic group (D-60). Water consumption in the non-diabetic animals treated 
with GFJ was similar to the control while treatment with insulin significantly (
Φ
P<0.0001) 
reduced the consumption of water. 
 
4.2 Fasting Blood Glucose and Fasting Plasma Insulin  
 
Fasting blood glucose (FBG) was significantly increased (^ P<0.0001) in the diabetic animal 
groups (D-60) and D-45 (*P=0.0002) when compared to the control respectively. Treatment 





P=0.0329 respectively when compared to their respective controls 
(Figure 21). FBG concentration in non-diabetic rats treated with GFJ (GFJ-ND) was similar 
when compared to the control. On the other hand fasting plasma insulin was significantly 
lower in the diabetic group (D-60) (^P<0.0001) and group (D-45) (*P=0.0002) when 



































































diabetic groups compared to the non-treatment diabetic group (D-45 and D-60). Insulin 
treatment on the other hand improved FPI significantly (*P<0.0001) when compared to the 
control (D60) Figure 22.  
 
Figure 21: The fasting Blood glucose levelsINS-60, insulin- diabetic 60mg STZ;  GFJ- ND, 
Grapefruit juice non-diabetic; GFJ-D45, Grapefruit juice -diabetic 45mg STZ ; GFJ-D60, 
Grapefruit juice diabetic 60mg STZ;  D-45 , diabetic – 45mg STZ; D-60 , Diabetic -60mg 
































































Figure 22: Fasting plasma insulin levels. INS-60, insulin- diabetic 60mg STZ;  GFJ- ND, 
Grapefruit juice non-diabetic; GFJ-D45, Grapefruit juice -diabetic 45mg STZ ; GFJ-D60, 
Grapefruit juice diabetic 60mg STZ;  D-45 , diabetic – 45mg STZ; D-60 , Diabetic -60mg 































































4.3 Glucose Tolerance Test 
 
Calculated area under the curve (AUC) from GTT curves show that diabetic animals (D-45 
and D-60) experienced significant (*P<0.0001) glucose intolerance in comparison to the 
control group (Figure 23 A and B). Treatment with GFJ significantly ( *P<0.0001) improved 
glucose intolerance  in  diabetic groups (GFJ-D 60) and (GFJ-D45) with GFJ when compared 
to the non-treated diabetic group (D60 and D-45) respectively (Figure 23).  


























Figure 23 A: Glucose Tolerance Test.INS-60, insulin- diabetic 60mg STZ;  GFJ- ND, 
Grapefruit juice non-diabetic; GFJ-D45, Grapefruit juice -diabetic 45mg STZ ; GFJ-D60, 















































Figure 23 B: Area under the curve (AUC) calculated from the fasting blood glucose levels. 
INS-60, insulin- diabetic 60mg STZ;  GFJ- ND, Grapefruit juice non-diabetic; GFJ-D45, 
Grapefruit juice -diabetic 45mg STZ ; GFJ-D60, Grapefruit juice diabetic 60mg STZ; D-45 , 
diabetic – 45mg STZ; D-60 , Diabetic -60mg STZ.( *P<0.0001; # p=0.0012; ^ p=0.0034) 
4.4 Glycogen Concentration in Hepatic Tissue  
 




Control 4.2±0.3*^ 7 






3.2 ±  0.5* 7 
Ins-D60 3.6 ± 07* 7 
GFJ-D60 4.9 ±0.5* 7 
*P value <0.05 vs Control, ^P value=0.0013 
Table 11: Effects of 8 week treatment with GFJ and insulin on hepatic glycogen 
concentration in non-diabetic and STZ- induced Diabetic rats. 
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The hepatic glycogen content in the diabetic control (D-60) was significantly (P=0.024) 
lower than the control group Table 11. Treatment with GFJ significantly (P=0.00016) 
increased hepatic glycogen content in the diabetic group (GFJ-D60) when compared to the 
untreated group (D60). In the non-diabetic animals (GFJ-ND), GFJ significantly increased 
(P=0.0013) hepatic glycogen content when compared to the control.  
 

























































































Figure 24: Urinary sodium (Na
+
) and potassium (K
+
) levels. INS-60, insulin- diabetic 60mg 
STZ;  GFJ- ND, Grapefruit juice non-diabetic; GFJ-D60, Grapefruit juice diabetic 60mg 
STZ;  D-60 , Diabetic -60mg STZ 
 




) and chloride ( Cl
-
) were significantly 
decreased ( *P = 0.032, 
#
P= 0.0075 and *P=0.0003 respectively) in diabetic group (D-60) in 
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  and Cl
-   
respectively when  compared to the untreated diabetic group D60 ( Figure 24 and Figure 25 








when compared to the control. Treatment with insulin did not cause a 






P=0.0036) increased urinary Cl
- 



























































































Figure 25: Urinary chloride (Cl
-
) and urea levels. INS-60, insulin- diabetic 60mg STZ;  GFJ- 
ND, Grapefruit juice non-diabetic; GFJ-D60, Grapefruit juice diabetic 60mg STZ;  D-60 , 
Diabetic -60mg STZ.  p*<0.0001,P^=0.0023 
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Urinary urea content was significantly (*P=0.0073) reduced in the diabetic group (D60) when 
compared to the control group. Treatment with GFJ (GFJ-D60) or insulin (INS-D60) did not 
cause a change in urinary urea excretion compared to group (D-60).  

























































































) levels.INS-60, insulin- diabetic 60mg 
STZ;  GFJ- ND, Grapefruit juice non-diabetic; GFJ-D45, Grapefruit juice -diabetic 45mg 
STZ ; GFJ-D60, Grapefruit juice diabetic 60mg STZ;  D-45 , diabetic – 45mg STZ; D-60 , 
Diabetic -60mg STZ 




 at the end of 8 week treatment with GFJ 
or insulin was not affected in all the groups (Figure 26).  
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Control 1.9±0.2 6.32±0.5 39.17±2.6* 7 
















Low 36.17±5.1 7 
GFJ-D60 1.59±0.03 4.37±0.8 33.50±3.5 7 
 
Table 12: Effect of Grapefruit Juice on Urinary Creatinine and Glomerular Filtration Rate. 
 
Urinary creatinine in the STZ-induced diabetic animals was too low and could not be 
detected by the analytical method used. Treatment of the diabetic groups with insulin did not 
alter urinary or serum creatinine but treatment with GFJ significantly (P=0.0266) increased 

























Figure 27: Photomicrograph of renal tissue of normal glomerular morphology control group 










Figure 28: Renal histologic lesions showing glomeruli hypertrophy in diabetic rats that were 
not treated (A) and normal glomeruli in those that were treated with GFJ (B). 
 
Part A of Figure 28 shows the morphological changes that took place in the untreated diabetic 
animal group (D-60). Treatment of the diabetic animals with GFJ –D60 prevented the 
development of renal hyper trophy (Figure 28 B). The structural morphology of the glomeruli 








The aim of this study was to investigate the effects of grapefruit juice on hyperglycaemia and 
renal water and electrolyte handling in STZ-induced diabetic rats.  Results from this study 
show that grapefruit juice lowered the blood glucose levels and consequently improved 
glucose intolerance in type1 and 2 diabetic models (GFJ-D45 and GFJ-D60) while improving 
renal electrolyte handling in STZ-induced diabetic rats.  
5.2. Hypoglycaemic Effects 
 
The administration of streptozotocin (STZ) 60 mg/Kg BW and 45 mg/Kg BW was done to 
produce type 1 (D60) and type 2 (D45) diabetic models respectively in this study.  The 
diabetic animals showed initial decrease in body weight but the type 1(D60) had significantly 
lost weight (Figure19) when compared to the control group and this could be due decreased 
effects of insulin action. Plasma insulin levels were measured in all the treatment groups with 
the diabetic groups (D45 and D60) having the lowest plasma insulin concentration (Figure 
22) inferring β-cell loss. Steptozotocin‘s affinity and specific toxicity to pancreatic β-cells 
resulted in the complete or partial destruction of the pancreatic β-cells resulting in decreased 
insulin production. Decreased insulin levels in the body are associated with an increase in 
plasma blood glucose concentration, decreased storage and synthesis of carbohydrates, 
proteins and lipids 
(138)
. The difference in body weight between type1 and type 2 diabetic 
models was due to the presence of low levels of insulin and or residual insulin in the D-45 
group resulting in decreased lipolysis and proteolysis processes in the tissues (Figures 19 & 
22). Weight reduction in diabetic group (D60) was possibly due to enhanced proteolysis, 
lipolysis associated with insulin deficiency. The treatment with GFJ or insulin resulted in 
improved weight gain. This suggests that GFJ could possibly reduce proteolysis and or 
lipolysis but the mechanism of action is still unclear. Fasting plasma insulin levels did not 
increase with the administration of GFJ suggesting that GFJ is neither insulinotropic nor β-
cell regenerative. In this study animal treatment with GFJ or insulin improved the weights of 
the diabetic animals and treatment of non-diabetic animals did not cause a significant change 
in the body weight compared to the control suggesting that GFJ does not affect the normal 




Excessive urination, was accompanied by polydipsia in the diabetic animals suggesting the 
presence of a diabetic state. These changes could particularly be attributed to the counter-
regulatory mechanisms in which the body tries to correct dehydration
 [26]
.  GFJ significantly 
reduced polydipsia in the diabetic group (D60-GFJ) compared to the non-treated diabetic 
group (D-60). Decreased polydipsia suggests improved blood glucose concentration in the 
diabetic animals due to improved diuresis. A decrease in plasma insulin levels was 
accompanied by an increase in FBG and glucose intolerance in diabetic group (D-60) when 
compared to the control group (Figures 21 and 23 B). Treatment with GFJ lowered FBG and 
improved glucose intolerance in diabetic groups (GFJ-D60 and GFJ-D45) when compared to 
untreated diabetic groups (D60 and D45) respectively. This was effect was not apparent in 
the insulin treatment group (INS-D60), where only FBG was reduced but glucose intolerance 
was still evident when compared to D60 (Figure 21 and 23B). This observation could be due 
to the fact that the dose of exogenous insulin (4U/Kg BW S.C b.d) used was not sufficient to 
improve glucose intolerance. Fasting plasma insulin was not affected when the non –diabetic 
group (GFJ-ND) was treated with GFJ compared to the control and when GFJ-D60 was 
treated and compared to group D-60. This suggests that GFJ does not stimulate insulin 
release and its hypoglycaemic effects could be due to other mechanisms like activation of 
AMPK. Previously the hypoglycaemic effect of GFJ was observed and reported by Owira 
and Ojewole 2009
 (37)
 from our laboratory when they compared GFJ effects and metformin in 
non-diabetic rats. It was also observed that GFJ did not increase plasma insulin levels in non–
diabetic rats. The current results confirm similar trend in diabetics.  
 
The hepatic glycogen content in the diabetic group D60 was lower when compared to the 
control. However, GFJ treatment increased hepatic glycogen concentration in both diabetic 
(GFJ-D-60) and non-diabetic (GFJ-ND) when compared to groups D-60 and control 
respectively (Table 11). The mechanism of action by which GFJ lowers blood glucose is not 
currently known but the results suggests that GFJ increases hepatic glycogen formation in 
hepatic tissues of diabetic and non-diabetic rats. This could be due to grapefruits effects on 
the key glycolytic enzymes involved in the metabolism of glucose in the liver. Studies have 
shown that flavonoids like naringenin and hesperitin found in grapefruit have the ability to 
lower blood glucose levels 
(30) (50) (79)
. Naringenin has been known to decrease the hepatic 
activity of glucose-6-phosphatase 
(61)
. In the liver glucose homeostasis depends upon the rate 
of gluconeogenesis and glyconeolysis
 (249)
. In the diabetic state enzymes like hexokinase, 
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glucokinase and phosphofructokinase don‘t function to their full potential because of 
insufficient insulin in the body 
(250)
 causing a decrease in hepatic glycogen concentration
 (251)
. 
In this study we did not determine to mechanism of action in which GFJ increases glycogen 
content and further studies will be required to elucidate grapefruits juice exact mechanism(s) 
of action. 
 
5.3. Effects of Grapefruit Juice on Renal Function  
 







) and  GFR in untreated diabetic group (D60) when compared to the control group (Figure 







when compared to the untreated diabetic group (D60) but in the non-diabetic group 
(GFJ-ND) GFJ treatment caused an increase in urinary K
+





compared to the control group. On the other hand insulin treatment of group (Ins-D60) 
caused an increase in urinary Cl
-
 but not Na
+
 or K
+   
when compared to the untreated diabetic 
group D60. Increased urinary output of K
+ 
was also observed in the non-diabetic rats and this 
effect is common with the consumption of fruit juices 
(80)
. To evaluate renal function urinary 
and serum creatinine in the diabetic group (D60) was analysed and urinary creatinine was 
undetectable by the analysis method used. In addition treatment with insulin did not change 
urinary creatinine but it increased serum creatinine levels. GFJ treatment on the other hand 
increased urinary creatinine but not serum creatinine . These results suggest that the STZ-
induced diabetic rats developed diabetic nephropathy in the course of the 8 week study 
period.  Sodium retention, chronic hyperglycaemia and reduced GFR are signs of renal 
dysfunction observed in animal models with declining renal function
 (252)
 .  
GFJ treatment in group GFJ-D60 caused an increase in urinary Na
+
 which was accompanied 
by an improvement in the GFR when compared to the untreated group D60. However insulin  
treatment did not improve GFR or urinary Na
+
 concentration. This could be explained by the 
fact that insulin possesses antinatriuresis properties independent of the actions aldosterone 
and GFR
 (231)
. Consequently serum electrolytes in the treated and untreated diabetic groups 
were not affected. This observation could be due to the fact that nephropathy was not severe 
enough to cause changes in the serum electrolyte levels or the body‘s counter regulatory 
mechanism was enough to correct the electrolyte imbalance. Na
+
 plays a major role in the 
determination of blood osmolality because it is the principal osmole in the extra cellular fluid 






reabsorbed in the proximal convoluted tubule is observed in the early stages of 
DM resulting in reduce urinary output due to tubular hypertrophy caused by increased 
glucose concentrations 
(253) (254)
. The inhibition of Na
+
 transporters in the proximal tubule in 
conjunction with reduced hyperglycaemia could be a major cause of decreased Na
+
 
reabsorption and increased urinary excretion. Sodium and glucose are transported together in 
the renal tubules via the SLGT1 and SLGT2 
(255) (252) 
and a study done by Li et al.
 (80)
 showed 
that the flavonioid naringenin  abundantly found in GFJ inhibited  renal and intestinal SLGT
 
(80)
. Renal tissues exposed to high glucose concentrations for a prolonged period of time are 
prone to structural and physiological changes. Severe hyperglycaemia observed in the 
diabetic animals is accompanied by changes in the brush border membrane to cater for the 





Glucose efflux from the tubule relies on the gradient created by Na
+
 dependent influx due to 
outwardly directed glucose gradient. Glucose induced toxicity can cause tubular injury 
(proximal tubules) in the kidneys of diabetic patients 
(255)
. The proximal tubule is the first 
segment of the nephron and helps in the maintenance of extracellular fluid volume. Animal 
studies done have shown that prolonged hyperglycaemia leads to the disruption of the tubule-
glomerular feedback mechanism in the renal tissues
 (253)
. Tubuloglomerular feedback involves 














caused by fractional reabsorption in the atrophic proximal tubules and this has been observed 
in IDDM and STZ-induced wistar rats
 [251]
. The change in fluid electrolyte concentration is 
sensed by the macula densa cells located in the distal convoluted tubule 
(256) 
and this causes 
an increase in single nephron glomerular filtration rate 
(252) (257)
. Water and sodium re-
absorption is increased with an increase in glucose concentration and this can be observed in 
diabetics
 (225)
. A reduction in Sodium reabsorption causes a decrease in the glomerular 
filtration rate (GFR) due to the disruption of the normal renal perfusion processes 
(252)
. 
Metabolic waste products like urea and creatinine are excreted principally by the kidney and 
renal injury is associated with reduced excretion and a concurrent reduction in GFR 
(258)
. 
Creatinine is a product of non-enzymatic dephosphorylative cyclization of phosphocreatine 
and urea levels are increased in the plasma are as a result of increased proteolysis 





. Creatinine has been used over the years to calculate creatinine 
clearance to evaluate kidney functions and disease conditions like glomerulonephritis, tubular 
necrosis and dehydration have been associated with low creatinine values
 (259)
. Low 
Glomerular filtration rate in patients with renal problems has been accompanied by fluid and 
electrolyte imbalances observed in the diabetic animals
 (258) (260)
. 
The transport of electrolytes in the kidney is mediated via different transport system in 
combination with neurohomanal influences. Renin and antidiuretic hormones (vasopressin, 
aldosterone) play an important role in the hormonal regulation of fluid electrolytes and water 
balance
 (261)











 transport by the proximal tubule and an exit for Na
+
 and the diabetic 
state has been shown to increase its activity in the kidney
 [253]
. In diabetic nephropathy 
activation of the PKC pathway, Na+/H exchanger activity, alteration of cell alkalinisation and 
change in intracellular calcium contribute to renal tubular hypertrophy and a consequent 
reduction in kidney functions
 (254)
.  
The changes in the renal electrolytes were accompanied by structural changes in the 
glomerulus as seen in figure 28 A of the untreated diabetic animals (D-60). Treatment with 
GFJ prevented the formation of histologic lesions GBM thickening and glomerular 
hypertrophy Figure 28 B. The results of this study provide the first in vivo evidence that 
suggests GFJ can ameliorate diabetic nephropathy by improving Na+ handling, GFR and 









The results obtained in this study showed grapefruits versatility as an antidiabetogenic agent. 
It managed to lower hyperglycaemia while improving glucose intolerance in STZ-Induced 
diabetic animals. Renal dysfunction observed in the diabetic animals was improved with GFJ 
treatment; Na+ retention was reversed accompanied by increased GFR as seen in the 
treatment groups. GFJ prevented the formation of histological lesions that contribute to the 
progression and development of diabetic nephropathy. The mechanism of actions in which 
GFJ works can be speculated to increase hepatic glycogen content and it might inhibit 
SGLT2 in the proximal convoluted tubule and prevent oxidative damage due to its powerful 
antioxidant effects ameliorating renal hypertrophy. 
 
6.1. Limitations of the Study  
 
The study did not investigate the mechanism of action in which GFJ lowers the blood glucose 
concentration and its effects on the glycolytic enzymes glucose-6-phosphatase and hepatic 
glucokinase. Lithium clearance was not performed on the STZ-Induced diabetic rats to 
determine the fractional excretion of sodium from the tubules as a measure of renal function. 
This was because .of time constraints and limited funds.  
 
6.2. Future Prospects and Recommendations for Further Study. 
 
This study has contributed to the body of knowledge in terms of the pharmacological effects 
of grapefruit juice in diabetic nephropathy but some questions are yet to be answered on the 
effects of C. paradisi on glycolytic enzymes; glycogen synthase and hepatic glucokinase. 
Further studies should be conducted on the effects of GFJ on proximal tubular Na
+ 
handling 
and renal hormones that affect Na
+
 homeostasis (Aldosterone and vasopressin).Determination 
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Reagent  Volume (ml) or Mass (g) 
Haemotoxylin  1g 
Distilled Water  1000ml 
Potassium Alum  1 50g 
Citric Acid  1g 
Chloral Hydrate  50g 
Sodium Iodate 0.2 g 
 
Distilled water was added to a 3L conical flask and the following reagents were added into it 
namely haemotoxylin, potassium alum and sodium iodate. The mixture was then boiled for 5 
minutes while constant stirring was maintained. After the five minutes the mixture was then 
cooled and filtered ready for use. 
 
1% Acid Alcohol 
 
Reagent  Volume (ml) 
70% Alcohol  70 
Concentrated Hydrochloric Acid  2 
Distilled Water  28 
 
The dilution process was done in a fume cupboard. 70 ml alcohol was mixed with 2mls of 
concentrated HCl and 28 ml distilled water. 







The initial steps are mentioned in the Materials and Methods section (3.1) the temporary 
mounted slides are then used in the following procedure: 
 
1. Stained with Mayers Haemotoxylin for 5 minutes. 
2. Washed under running water until all excess stain was removed and the tissue 
appearedbluish. 
3. The slides were then differentiated in acid alcohol. 
4. Stained with Eosin for 10 minutes. 
5. Washed under running tap water for 3 minutes. 








a) Celestine Blue solution 
 
Reagent  Volume (ml) or Mass (g) 
Celestine blue B  2.5g 
Ferric ammonium sulphate  25g 
Glycerin  70ml 
Distilled Water  50ml 
Distilled water was used to dissolve the ferric ammonium sulphate. Continued stirring was 
maintained as the Celestine blue B was added and then the mixture was then boiled.  The 
mixture was then cooled and glycerin was then added. 
  
b) 1% acid solution  
 




3. Acid Fuschin Solution 
 
Reagent  Volume (ml) or Mass (g) 
Acid Fuschin  0.5g 
Glacial Acetic Acid  0.5ml 
Distilled Water  100ml 
 
Glacial acetic acid was placed in a beaker and a mixture of distilled water and Acid Fuschin 
was added to it and stirred. 
 
4. Phosphomolybdic Acid solution 
 
Reagent  Volume (ml) or Mass (g) 
Phosohomolybdic Acid  1g 
Distilled Water 100ml 
 
1gram of the Phosohomolybdic acid was dissolved in 100ml of distilled water. 
 
5. Methyl Blue Solution 
 
Reagent  Volume (ml) or Mass (g) 
Methyl Blue  2g 
Glacial Acetic Acid  2.5ml 
Distilled Water 100ml 
2g of Methly Blue was dissolved in distilled water then added into the glacial acetic acid . 
 
Procedure 
The initial steps are mentioned in the Materials and Methods the temporary 
Mounted slides are then used in the following procedure: 
 
1. The nuclei were stained using Celestine blue for 5 minutes. 
2. The slides were rinsed using distilled water. 
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3. The tissues were then immersed in Mayers Haemotoxylin for 5 minutes. 
4. The slides were washed till they appeared bluish. 
5. The tissues were differentiated using acid alcohol. 
6. The slides were transferred to acid fuschin solution for 5 minutes. 
7. The slides were rinsed using distilled water. 
8. Slides were treated using phosphomolybdic acid for 5 minutes and then drained. 
9. The slides were stained with methyl blue for 5 minutes. 
10. The slides were rinsed using distilled water. 
11. They were then treated with acetic acid for 2 minutes. 




















Appendix 4- Equipment used  
 
Blood collection kits: Vacationers with red and green tops for serum and plasma collection 
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